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ABSTRACT
Cardiovascular diseases (CVDs) are the leading cause of death worldwide in
males (XY) and females (XX). Prior to menopause, females have a relative protection
against serious cardiac pathologies compared to age-matched males. This phenomenon is
widely attributed to the ovarian hormone estrogen. Unfortunately, hormone replacement
therapy to maintain estrogen levels in postmenopausal females has overall adverse
effects, and it is not recommended for long-term use or as a preventative measure for
eCVDs. A major driver of CVDs, specifically heart failure, is cardiac fibrosis: the
continued buildup of scar tissue that reduces the heart’s ability to pump. There are
currently no FDA-approved therapies to specifically target cardiac fibrosis, and the fiveyear survival rate for patients diagnosed with heart failure is typically under 50%.
Recent studies exhibit the potential of estrogen to decrease the fibrotic response
of cardiac fibroblasts, the cells responsible for the progression of fibrosis. However, most
of these studies were conducted on tissue culture plastic (TCP) and/or with pooled male
and female neonate rat CFs, limiting their clinical relevance. The goal of this dissertation
is to expand our understanding of the sex-specific signaling of estrogen within CFs using
in vitro and in silico techniques to identify potential sex-specific dimorphisms in
regulatory signaling that will allow for the creation of novel treatments of cardiac fibrosis
that mimic estrogen’s therapeutic abilities while negating its adverse systemic effects.
Biological sex impacts the presentation, prognosis, and severity of many
conditions. Yet, females have been historically underrepresented in clinical trials and
experimental studies, resulting in health inequities that disproportionately affect women.
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Literature has shown that women are more likely to include female samples in their study
design and report sex-disaggregated data. However, they have been consistently
underrepresented in STEM fields. Increasing the number of female scientists will aid in
shrinking the gender data gap, which will help elucidate our understanding of the sexspecific differences of various diseases and biological functions. In addition to my in
vitro and in silico initiatives, I have developed in classroom techniques utilizing inclusive
pedagogy strategies that specially target female students with an aim to increase their
STEM self-efficacy and identity. These in vitro, in silico, and in classroom techniques are
designed with the intention of fostering a more inclusive and equitable approach to
healthcare.
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CHAPTER ONE
INTRODUCTION
1.1 Study Significance
Cardiovascular disease is the leading cause of death in both males (XY) and females
(XX). However, it has been widely observed that females have a relative protection against
serious cardiac problems prior to menopause, likely due to the ovarian hormone estrogen.
One of the leading contributors to heart failure is cardiac fibrosis, a continued buildup of
extracellular matrix driven by cardiac fibroblasts (CFs) in response to both biochemical and
biomechanical stimuli. There are currently no therapies approved to specifically target
cardiac fibrosis, but there have been many studies that exhibit the potential of estrogen to
decrease the fibrotic response of CFs. Notably, hormone replacement therapy (HRT) has
been correlated to a decrease in mortality due to fibrotic-induced heart failure in
postmenopausal females. Unfortunately, studies also show that HRT can elevate other risk
factors, including cancer and stroke, and is currently not recommended for long-term use.
Recent literature has elucidated the role of estrogen in CF signaling in responses to
biochemical stimuli; however, the majority of these studies were conducted on tissue
culture plastic (TCP) and/or with pooled male and female neonate rat CFs. The goal of this
dissertation is to expand our understanding of the sex-specific signaling of estrogen within
CFs using in vitro and in silico techniques to identify potential sex-specific treatment
recommendations for cardiac fibrosis that mimic estrogen’s therapeutic sec abilities while
negating its adverse systemic effects.
An additional aim of this dissertation is to increase the female-specific data in the
literature related to cardiovascular diseases (CVDs). Biological sex is known to impact the
presentation, prognosis, and severity of many conditions, including CVDs. Unfortunately,
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females have been historically underrepresented in clinical trials and experimental studies.
This has resulted in many health inequities that disproportionately affect women, including
adverse drug responses occurring at double the rate in females than in males. As there is a
push to develop artificial intelligence that enables patient-specific diagnostic and treatment
recommendations through precision medicine, it is imperative to increase the amount of
female data in the literature to have robust sex-disaggregated data sets to train and validate
these algorithms.
Literature has shown that female-specific data is more likely to be considered and
reported if either the first or last author of a manuscript is female. Increasing the number of
female scientists will aid in expediting the understanding of female-specific data in the
literature and our overall understanding of the sex-specific differences of various diseases
and biological functions. In addition to my in vitro and in silico initiatives, I have also
developed in classroom techniques that specially target females who have been historically
underrepresented in STEM with an aim to increase their self-efficacy of computational
methods and STEM identity. The in vitro, in silico, and in classroom techniques outlined
below are designed with the intention of fostering a more inclusive and equitable approach
to healthcare.
1.2 Specific Aims
Aim 1: Test the Effects of Sex and 17 β-Estradiol on Cardiac Fibroblast Morphology and
Signaling Activities In Vitro
Several studies have demonstrated estrogen’s cardioprotective abilities in decreasing
the fibrotic response of cardiac fibroblasts (CFs). However, the majority of these studies are
not sex-specific, and those at the cellular level utilize tissue culture plastic, a substrate with
a much higher stiffness than physiological conditions. Understanding the intrinsic
11

differences between male and female CFs under more physiologically “healthy” conditions
will help to elucidate the divergences in their complex signaling networks. We aimed to do
this by conducting a sex-disaggregated analysis of changes in cellular morphology and
relative levels of profibrotic signaling proteins in CFs cultured on 8 kPa stiffness plates with
and without 17 β-estradiol (E2). Cyclic immunofluorescent analysis indicated that there was
a negligible change in cellular morphology due to sex and E2 treatment and that the
differences between male and female CFs occur at a biochemical rather than structural
level. Several proteins corresponding to profibrotic activity had various sex-specific
responses with and without E2 treatment. Single-cell correlation analysis exhibited varied
protein-protein interactions across experimental conditions. These findings demonstrate the
need for further research into the dimorphisms of male and female CFs to develop better
tailored sex-informed prevention and treatment interventions for cardiac fibrosis.
Aim 2: Screen for Sex-Specific Drug Effects in a Fibroblast Network Model Integrated with
Estrogen Signaling
A previously developed large-scale signaling network model (SNM) of cardiac
fibroblasts was updated to include estrogen signaling. Male, female, and averaged pooled
SNMs were developed by varying the weighting of estrogen stimulation of its three primary
receptors. These models were validated against over peer-reviewed studies and found to be
77% accurate in matching simulation predictions to experimental outcomes in the literature.
Additionally, sex-specific drug screens of 36 unique drug targets in the model were
conducted with three experimental conditions: male, female post-menopausal, and female
pre-menopausal. The cardioprotective effect of estrogen in the female pre-menopausal
condition was evident; however, sex-specific differences between the male and female postmenopausal screens were much more subtle. Several regulatory pathways were identified
that warrant further study in understanding the divergences in male and female cardiac
12

fibroblasts signaling. Additionally, we recommend the inclusion of more patient-specific
parameters (i.e., genomic and transcriptomic data) in future model advancement to enhance
its ability to make sex-specific predictions.
Aim 3: Development of Systems Biology Education Modules Utilizing Inclusive Pedagogy
Strategies
There has been a persistent gender and racial gap in STEM. Recruitment and
retention of these historically marginalized individuals are crucial to ensuring that there are
diverse design teams as a way to combat inequities in healthcare. Five systems biology
education modules were developed with inclusive pedagogy strategies designed to foster
STEM identity and self-efficacy regardless of previous computational experience. Each
module lesson plan is grounded in active learning techniques and consists of an unplugged
activity, a model tutorial, and an open-ended model advancement exercise. Modules are
focused on various biological and disease phenomena (e.g., tumor growth, viral spread,
allergic reaction, gene regulation, and the menstrual cycle). The modules are available on
the lab GitHub and will be piloted with the summer 2022 cohort of Clemson’s Emerging
Scholars program. During the piloting, we aim to assess student reception of the modules
and investigate the use of representative problem statements (i.e., female students asked to
model the menstrual cycle) on STEM identity, self-efficacy, and team dynamics.
1.3 Sex and Gender Terminology
Health disparities due to sex and gender are often integrally related. In this
manuscript, sex refers to biological differences due to chromosomal genetic makeup (i.e.,
male=XY and female=XX). Gender refers to the societal and behavioral factors that
influence a human’s identity and actions (i.e., man/men= identify using he/him pronouns
and woman/women= identify using she/her pronouns). Sex and gender will often be
13

referred to as a dichotomy throughout this manuscript. Still, we also acknowledge that for
many patients, they are a spectrum that can result in additional complexities related to
health care.
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CHAPTER TWO
A REVIEW OF THE LITERATURE
2.1 Heart failure in cardiovascular diseases
2.1.1 Current trends and statistics
Cardiovascular diseases (CVDs) are consistently the world’s leading cause of death,
accounting for 1/3 of deaths worldwide1. In the United States (U.S.), an estimated 659,000
people die of CVDs each year2. CVDs include a multitude of pathologies, including stroke,
coronary artery disease, arrhythmia, high blood pressure, heart failure, and myocardial
infarction (MI). Stroke and MI are typically the deadliest of these pathologies as their
sudden onset can result in death within hours without medical treatment. However, as
knowledge of warning signs has increased over the past several decades in the U.S., there
have been substantial increases in patient survival rates, especially for a MI3,4. If patients are
hospitalized and receive treatment for an initial MI, survival rates are generally reported at
or above 90%5.
However, the long-term survival remains low, with 1-year survival rates dropping
by about 10% and consistently declining in subsequent years due to the development and
progression of heart failure (HF)- a pathologic condition in which the heart is not able to
adequately supply blood to the rest of the body5,6. Currently, the five-year survival rate of
HF is most often reported as 50% or less7. HF presently afflicts about 6.2 million
Americans and was considered a cause of death in 13.4% of all deaths in 20188. Due to
these continued increases in short-term survival rate after an initial MI coupled with rising
rates of CVDs, rates of HF are also expected to continue to increase by 43% by 20309.
2.1.2 Cardiac fibrosis disease progression and treatment
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HF occurs after an initial MI due to the deposition of collagens and other
extracellular matrix (ECM) proteins that are necessary to maintain structural stability in the
infarct region. However, even after scar tissue has formed in the infarct area, this collagen
deposition can continue uncontrolled resulting in excessive cardiac fibrosis. Fibrosis is
defined as the development of fibrous connective tissue or “scar tissue” in regions that
intrude on healthy tissue10. It most often occurs in the lungs (i.e., cystic fibrosis and
pulmonary fibrosis), the liver (cirrhosis), the kidneys (renal fibrosis), and the heart (cardiac
fibrosis)11. When it occurs in the heart, it can result in reduced ejection fraction because of
left ventricle thickening and arrhythmia due to interruptions in electrical signaling due to
the excess scar tissue12. As conditions become more pathologic, the heart must work harder
to pump blood to the rest of the body, exacerbating fibrotic conditions.
There are currently no FDA-approved treatments to directly target cardiac fibrosis13.
Patients diagnosed with HF are often prescribed a cocktail of angiotensin-converting
enzyme (ACE) inhibitors and beta-blockers which can lower blood pressure and help
control cardiac signaling14. Although these drugs can mitigate HF symptoms, which can
slow the progression of fibrosis, they will not reverse or completely stop continued fibrosis.
This is especially troubling because HF can be difficult to diagnose. Although patients who
have suffered an initial MI are routinely put on preventive treatments to slow the
progression of HF, not all HF results from a MI. Coronary artery disease (CAD), high blood
pressure, viral-induced myocarditis, and congenital heart defects are also common causes of
HF. A diagnosis of HF usually requires a multitude of tests, including an electrocardiogram
(ECG), blood test, chest X-Ray, and stress test that are often not conducted until the disease
has advanced to a stage where symptoms are interfering with a patient’s everyday life.
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It can be challenging to predict which patients are most at risk of developing severe HF.
Common risk factors include smoking and alcohol abuse, diabetes, a diagnosis of another
cardiac pathology, and obesity. However, HF due to congenital heart defects and viralinduced myocarditis can remain undetected for decades before diagnosis. Recently, viralinduced myocarditis has become an area of increased interest due to the COVID-19
pandemic15. Initial research has exhibited a fraction of patients develop inflamed cardiac
tissue after infection with COVID-1916. However, it is currently impossible to predict which
patients are the most at risk for this complication and what lasting effects this may have.
There is a clinical need to develop new diagnostic and treatment mechanisms for
cardiac fibrosis. In addition to the millions of patients worldwide suffering from the disease,
HF’s healthcare-related costs typically surpass $30 billion annually. This number is
expected to double by 2030 if interventions are not taken17. Many researchers are focused
on developing novel treatments and more accurate diagnostic capabilities. Still, remedies
remain elusive due to the complexity of the disease, including the various biochemical and
biomechanical factors that fuel it. In addition, it is believed that biological sex likely plays a
role in the development of cardiac fibrosis. Yet, minimal research has focused on the sexspecific hormonal and genetic mechanisms that contribute to the development of cardiac
fibrosis.
2.2 The effect of biological sex on cardiovascular disease
2.2.1 Historical context
Biological sex and gender can significantly impact the presentation, diagnosis, and
treatment of many diseases, including CVDs. The most notable instance of this is the
misconception that chest pain is the hallmark symptom of a heart attack. While this is true
for males and even some females, it is more likely for females to experience more subtle
17

symptoms such as chest pressure, neck pain, and nausea18. This phenomenon, named the
Yentl Syndrome, has resulted in misdiagnosis and ineffective treatment of heart attacks in
female patients due to their different symptoms than male patients19. This misunderstanding
has resulted from decades of underrepresentation of female data in research and clinical
trials, which has compounded into a poor understanding of the differences between male
and female cardiovascular health, resulting in inaccuracies in the diagnosis and treatment of
CVDs that disproportionally affect women.
Until recently, heart disease was misconstrued as a “man’s disease.” This is best
illustrated by the media, which often portrayed and targeted men as the most likely victims
of a heart attack20,21. As CVDs are also the leading cause of death in women, this is
inaccurate and a harmful serotype to women’s health. It is true, however, that females
typically develop CVDs 7-10 years later in life than males22. This is primarily thought to be
due to the cardioprotective role of the ovarian hormone estrogen23. Premenopausal females
have higher estrogen levels, which reduces their risk of developing cardiac pathologies.
However, once they have undergone menopause and the resulting decrease in estrogen
production, this cardioprotection subsides. Because of this, hormone replacement therapy
(HRT) which maintains estrogen levels in menopausal females, was believed to be the
solution for a brief time24. However, after randomized clinical trials in 2002 by the
Women’s Health Initiative (WHI), HRT was found to elevate the risk of stroke, cancers,
and even heart attack and therefore is not recommended for long-term use to prevent
CVDs25.
Clinically, there have been many sex-specific findings related to cardiac fibrosis.
Females are typically observed to have less fibrotic tissue than age-matched males in
healthy and diseased contexts23. In a longitudinal study of patients aged 45-84 who enrolled
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without CVDs, it was found that focal myocardial scarring was 5xs higher in males versus
females by the ten-year mark. In addition, these patients typically presented with increased
concentricity and preserved ejection in females and greater left ventricular dilation and
reduced ejection fraction in males, indicating a sex-specific correlation in fibrotic
remodeling26. These trends in a sex-specific correlation of fibrotic remodeling are also
observed in other organs which can undergo pathologic fibrosis, such as the lungs, liver,
and kidneys11. Just as estrogen is believed to impact overall cardiovascular health, several
studies have reported that post-menopausal females have increased fibrosis markers
compared to males, indicating that gonadal hormones likely play a role in these sex-specific
trends related to fibrosis11,23,27.
1.2.2 Estrogen mitigates cardiac fibrosis
Even though estrogen is not currently approved as a cardioprotective agent, there
have been several notable instances clinically and in the lab since the 2002 WHI trials
where it has shown evidence in reducing the severity of HF. In a retrospective 2003 study
by Lindenfield et al., it was found that female patients who took beta-blockers in
conjunction with HRT showed a significant reduction in mortality in females with
nonischemic HF compared to those just taking beta blockers28. Currently, researchers
hypothesize that the timing of HRT may play a role in its efficacy. Recent studies have
shown that when females take HRT earlier in life, closer to the time they undergo
menopause, it effectively reduces CVDs29,30.
These findings are supported by a multitude of in vivo and in vitro studies that report
decreases in HF markers after estrogen treatment. For example, Pedram et al. demonstrated
reductions in angiotensin II (AngII) induced increases in collagens and alpha-smooth
muscle actin (α-SMA) upon treatment of 17-β estradiol (E2). This was confirmed via an ex
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vivo analysis of AngII and E2 treated ovariectomized (OVX) mice. Mice who had received
E2 treatment had hearts that were notability smaller than the hearts of just AngII treated
mice, indicating preserved left ventricle wall thickness and lower markers of fibrosis in
histology in the E2 treated mice31. Additionally, Iorga et al. found that estrogen therapy
restored ejection fraction in male and female mice with pressure-overloaded induced HF32.
These findings demonstrate the need for further study of estrogen’s role in CVDs to
possibly find a way to mimic estrogen’s therapeutic abilities while mitigating its harmful
effects.
2.2.3 Other sex-specific biologically relevant influences
Hormonal differences between male and female hearts are often not observed before
puberty. There are only slight differences in male and female overall body size at birth and
until their preteen years. However, after puberty, on average, males grow larger than
females; these differences in body proportions are also reflected in heart mass, with adult
female hearts being 1/4th smaller than adult male hearts33. Because of their different heart
sizes, there are functional differences between male and female hearts, such as rhythms and
rates. For example, males typically have a resting heart rate of 70-72 beats per minute
(BPM), and females have one of 78-82 BMP to attain similar blood volume outputs34.
However, not all of the physiological differences between male and female hearts
and CVDs are believed to be solely due to hormones. Recent literature has also suggested
genetic differences that persist regardless of gonadal hormones are also likely contributing
to the dimorphisms in CVDs in males and females. At the macro level, male and female
hearts often have different ratios of the cell types which make up the heart (e.g., myocytes,
fibroblasts, smooth muscle cells, endothelial cells, valve cells, and macrophages)35. It is
currently unclear how these different ratios may contribute to physiological differences that
20

affect cardiovascular health. At the microlevel, each cell is believed to have a sex associated
with the chromosomal genotype (i.e., male cells= XY and female cells= XX). Gene
ontology within the multiple cell types of the heart has also shown differences in the
expressed genes between male and female cells, indicating that there are intrinsic sex
differences that could contribute to the sex-specific differences in CVDs35. For example, in
a recent study by Aguado et al., it was found that genes that escape X-chromosome
inactivation were responsible for regulating some of the sex-specific differences observed in
aortic valve stenosis, a pathology similar to cardiac fibrosis36. More research needs to be
conducted to fully understand how these genetic differences combined with hormonal
differences affect CVDs.
2.2.4 Sex-disaggregated data reporting
Much of this current lack of understanding of the sex-specific differences in CVDs
can be attributed to the historical lack of representation of female data in clinical trials and
the literature. We also want to acknowledge that although we are focused on the gender gap,
this lack of representation is only further compounded if considering factors such as race,
ethnicity, and socioeconomic background. Although current guidelines by the Food and
Drug Administration (FDA), National Institutes of Health (NIH), and American Heart
Association (AHA) require female samples/participants in experimental design, this is a
recent development. Males, typically Caucasian, have been formally and informally
considered the “norm” for medical research for centuries37,38. This has been exacerbated by
systemic issues such as medical distrust and the misconception that female hormones are
unpredictable and can skew experimental results. From 1977 to 1993, the FDA actively
excluded women of childbearing age from participating in clinical trials in response to fetal
malformations caused by thalidomide39. Additionally, it was not until 1998 that the FDA
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required gender-based reporting of their phase II drug applications40. And although the NIH
publicly supported the inclusion of women in clinical research since the 1990s, it was not
until 2016 that the NIH implemented a guideline requiring the use of both sexes in
vertebrate animal research41. These decades lacking female representation have resulted in
many clinical trials and published literature skewed toward male data. Even in studies that
use male and female samples, unless they are specifically investigating the effect of
estrogen or sex, most published literature on in vivo and in vitro studies do not report results
in a sex-disaggregated manner. This lack of representative data has resulted in many health
disparities affecting women. The first FDA-approved artificial heart was designed only for a
male build42. Additionally, adverse drug reactions occur at double the rate in females
compared to males43.
2.2.5 Experimental models to study sex-specific effects
Part of the reason for this lack of sex-disaggregated data in the literature is a result
of poor experimental models to study hormonal-based differences. As humans and whales
are the only mammals to undergo menopause, there are no good animal models to
completely replicate the gradual onset of menopause and its implications for women’s
health44. As I briefly discussed earlier, it is believed that premenopausal females have a
relative cardioprotection compared to age-matched men, so this is especially relevant to
CVDs. In an in vitro setting, researchers typically treat cells with 17-beta estradiol to
evaluate hormonal sex differences23,45–48. Few studies investigate how other sex hormones,
including testosterone and progesterone, can also modulate sex-specific disease responses.
Many commercially available human fibroblast cell lines are pooled and/or do not report the
cell sex. For in vivo and ex vivo studies focused on hormonal differences, ovariectomized
(OVX) mice or rats are often used49. However, this model is more representative of sudden
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menopause (i.e., a hysterectomy) rather than the gradual perimenopausal state females are
in for several years. Knockout animal lines have also been developed to study the specific
effect of a particular estrogen receptor50.
These models are limited in scope as they primarily study hormonal differences; it is
also essential to discern intrinsic biological differences. Much of the current literature on
HF either uses pooled neonatal cells, male cells, or cell sex is entirely unreported. There
needs to be a shift in reporting practices to fully capture which sex-specific disease
responses are due to intrinsic biological differences, which are due to hormones, and which
are due to a combination. This will first require a greater understanding of the complex
signaling pathways in cardiac fibroblasts.
2.3 Cardiac Fibroblast Signaling
2.3.1 Biochemical signaling
Cardiac fibroblasts are the cells responsible for the extracellular matrix (ECM)
deposition in the heart. In a healthy myocardium, they contribute to the biomechanical,
biochemical, and electrical homeostasis of the heart primarily through their regulation of
collagen turnover. In a pathologic environment, such as immediately after a myocardial
infarction (MI), they maintain structural stability by rapidly secreting collagens and other
ECM proteins to create scar tissue to patch together the infarct region. However, this ECM
deposition can continue uncontrolled resulting in fibrosis due to the disruptions in normal
cell biochemical and biomechanical signaling.
The primary biochemical pathways involved in cardiac fibroblast signaling include
inflammatory cytokines, growth factors, and paracrine signaling. Upon cardiac injury,
immune cells induce a pro-inflammatory response by releasing cytokines such as tumor
necrosis factor-α (TNFα), interleukin 1(IL-1), and interleukin 6 (IL-6), which can induce
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the secretion of metalloproteinases (MMPs) to clear necrotic tissue51,52. Latent transforming
growth factor-beta (TGFβ) is present in the ECM and can be activated and induce
proliferation and ECM deposition, causing a significant downstream response in pathways
involving SMAD3 and MAPK53. Collagen 1 and Collagen III (col-I and col-III) are secreted
by fibroblasts as the main component of the infarct scar. Hormonal agonists angiotensin II
(AngII), norepinephrine (NE), natriuretic peptides (NPs), and endothelin-1 (ET-1) are also
activated during the post-inflammatory response and can continue to alter ECM related gene
expression during the remodeling phase of the scar creation54.
2.3.2 Biomechanical signaling
Like most cells, cardiac fibroblasts respond not only to chemical stimuli but also to
mechanical stimuli. In a post-MI environment, the heart undergoes structural changes that
affect the strain, stress, pressure, and stiffness that cardiac fibroblasts experience. These
biochemical changes can cause intracellular responses via mechanotransduction. A cardiac
fibroblast can sense changes to its biomechanical microenvironment through receptors on
the plasma membrane, cytoskeleton, and nucleus and convert these to a biochemical
response. Integrins form focal adhesion complexes on the plasma membrane that connects
to the intracellular actin skeleton and can directly respond to biomechanical cues. For
example, focal adhesion kinase (FAK) responds to increases in stiffness to activate the
MAPK pathway55. In the cytoskeleton, increases in mechanical stress can cause the
transformation of G-actin, which is typically present in low tension environments, to Factin56. This releases myocardin-related transcription factors (MRTF) and allows them to
enter the nucleus, where it can alter gene expression. Linker of the nucleoskeleton and
cytoskeleton (LINC) is primarily responsible for the direct nucleus responses to
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mechanotransduction by connecting the cytoskeleton to the nucleus and controlling
chromatin packaging55.
Understanding a cardiac fibroblast’s response to its mechanical environment is
fundamental. The majority of in vitro research investigating cardiac fibroblasts is conducted
on tissue culture plastic (TCP), which has a stiffness magnitudes higher than in vivo
stiffness, even a fibrotic one. The acknowledgment of mechanical stimulation as an
essential consideration in cardiac fibroblast research is becoming more accepted, and softer
polydimethylsiloxane (PDMS) and polyacrylamide (PA) substrates are becoming more
widely used. However, the default is often still TCP which can make translating more
complex signaling mechanisms of cardiac fibroblast signaling to an in vivo context difficult.
2.3.3 Estrogen signaling
One such complexity is estrogen signaling within cardiac fibroblasts. I mentioned
briefly earlier (section 2.2.5 Experimental models to study sex-specific effects) that most
estrogen signaling studies within a cardiac fibroblast context were conducted with neonatal
cells. However, this pools male and female cells together, so a sex-disaggregated analysis is
impossible. Compounding this, nearly all of the few studies that conducted a sexdisaggregated analysis are done on TCP, so it is difficult to fully ascertain how male and
female cardiac fibroblasts are inherently different under physiological conditions23.
Like other biomolecules, estrogen is integrated into the cell via receptors located on
the plasma membrane. Male and female cardiac fibroblasts are known to have different
levels of the three primary estrogen receptors: estrogen receptor alpha (ER-α), estrogen
receptor beta (ER-β), and G-protein coupled estrogen receptor (GPR30)57,58. This translates
to divergences in intracellular signaling pathways that impact the progression of fibrosis in
a sex-specific manner. Westphal et al. found that treating with an ER-α agonist reduced
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signs of fibrosis in mice who had undergone transverse aortic contraction in female OVX
mice59. Additionally, it was found that ER-α downregulates collagen I and III in female rat
cardiac fibroblasts upon estrogen treatment, while ER-β can upregulate collagen I and III in
male rat cardiac fibroblasts upon estrogen treatment45.
Several studies have begun to elucidate the mechanism of the pathways downstream
of these estrogen receptors in cardiac fibroblasts. For example, Pedram et al. showed that
estrogen treatment competitively inhibited angiotensin II and endothelin 1 profibrotic
activity by blocking TGFB induced SMAD activation downstream of ER-β31. GPR30 was
found to attenuate cardiac fibroblasts proliferation via inhibiting Cyclin Beta 1 and CDK1
pathways60.
Medzikovic et al. reviewed the current understanding of estrogen signaling within
cardiac fibroblasts (see Figure 2.1)23. Although this review includes many downstream
pathways and some sex-disaggregated results, no biomechanical cues are included in the
schematic. Studies investigating estrogen’s involvement in biomechanical pathways have,
to our knowledge, only been published in regards to osteoporosis or other bone contexts61–
63

. Future studies must consider how biomechanical cues may affect estrogen signaling

pathways within cardiac fibroblasts to fully leverage estrogen's cardioprotective abilities
while mitigating its harmful effects.
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Figure 2.1 Current understanding of downstream estrogen signaling within cardiac fibroblasts.

2.4 Systems Modeling
2.4.1 Systems modeling of cardiac fibroblasts
One way to facilitate the understanding of complex signaling pathways is using
computational models. In silico experiments are generally cheaper and faster than trial and
error wet-lab experiments alone. In particular, signaling network models can be a handy
tool for understanding complex systems-level biology. Such models have been around for
decades and have provided essential insights further validated in vitro/in vivo64,65. Recently,
computational models have been applied to identify potential new drug targets and
diagnostic tools.
A computational signaling network model of cardiac fibroblasts was developed and
published previously by Ziegler and Richardson et al. and included 10 signaling pathways
comprised of 91 nodes and 134 reactions66. This model was validated and predicted to
match the input/outputs of 80% of 82 independent published experiments. The model
functions via a series of logic-based ODE representing different activation and intracellular
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inhibitory reactions through AND and OR gates. The first iteration of this model only
included one mechanical input and did not include mechanotransduction reactions. Our lab
(Rogers et al.) updated the model to include mechanosensitive pathways (109 nodes and
174 reactions)54,67. One major limitation of this updated model is that it is not sex-specific
and consists of no gonadal hormones, both of which are essential considerations in the
disease progression of cardiac fibrosis (see section 2.3.3 Estrogen signaling).
2.4.2 Sex-specific systems modeling
Sex-specific computational models have been created in a variety of disease contexts.
Ahmeed et al. created a sex-specific model of blood pressure regulation68. Chen et al.
developed a sex-specific model of renal activity to study nitric oxide bioavailability69.
However, to our knowledge, no sex-specific disease models have been created to investigate
cardiac fibrosis. There has been a push to make patient-specific models through precision
medicine techniques. Our lab’s cardiac fibroblast model has been used to make personalized
patient predictions after integrating transcriptomic data from patient sera70. However, a
concern with this technique is that the data used to create and validate these seemingly
gender-neutral patient-specific models is often skewed toward male data. As discussed
previously (section 2.2.4 Sex-disaggregated data reporting), female data have been
historically lacking in clinical and experimental research. The papers used to validate the
current cardiac fibroblast model were 30% male and 0% female (70% were pooled neonates
or unreported). These models will likely be more accurate for male patients than female
patients unless female data is intentionally incorporated to train and validate the models.
2.4.3 Systems modeling for drug discovery
Many signaling network models are designed to aid in drug discovery, making it
imperative that female data be considered during their design and validation. Currently,
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adverse drug responses (ADRs) occur at double the rate in females compared to males, most
likely due to their underrepresentation in clinical trials43. In a review of 9 significant heart
failure drug trials, women made up only 24% of the patients enrolled in the trials71.
Interestingly, literature has suggested that many ADRs occur in a sex-specific manner. In a
study that investigated the pharmacokinetics (PK) of 86 FDA-approved drugs, it was found
that PK values were correlated to sex, and 96% of drugs with female-biased PKs were
associated with higher risks of ADRs72. These ADRs typically occur because of differences
in drug absorption, metabolism, distribution, and elimination between males and females.
For example, Warfarin protein binding is known to be influenced by estrogen and
testosterone71. Despite higher plasma levels in females, beta-blockers were found to be less
effective at lowering heart rate in females compared to males71.
Unfortunately, many drug trials do not report sex-disaggregated data on ADRs, so
an understanding of the sex-specific risks is only beginning to be understood. A recent
study that investigated the sex-specific ADR reporting on common HF medications (e.g.,
angiotensin-converting enzyme inhibitors, β-blockers, angiotensin II receptor blockers,
mineralocorticoid receptor antagonists, ivabradine, and digoxin), of the 155 records
investigated only 7% reported ADR separately for males and females43. Much of this data
will be very difficult to reproduce retroactively without additional clinical trials. However,
sex-specific drug screens using in silico models could hasten this process by identifying
drugs on the market that are most influenced by biological sex.
A collaborator recently conducted a large-scale drug screen with our cardiac
fibroblast model73. This drug screen resulted in a few recommendations (i.e., Galunisertib)
of potential drug targets for developing a therapeutic for cardiac fibrosis. However, this
screen was not sex-specific. There are currently no sex-specific treatment recommendations
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for the management or treatment of cardiac fibrosis. However, as disease presentation and
progression of cardiac fibrosis can occur in a sex-specific manner, it is an essential
consideration for future research.
2.5 Gender Gap in Education
Evidence has shown that papers are more likely to report sex-specific findings if the
first or last author is female74. However, many science, technology, engineering, and math
(STEM) fields remain predominately male-dominated. Women make up only about 15% of
the engineering workforce75. And although this trend is less severe for life science related
fields such as biomedical engineering, which is more female-dominated (47% of the
workforce) than many other engineering disciplines, this is not the case for computational
areas76. Women make up only 20% computational biology workforce77. Because of these
trends, design teams are often heavily male-dominated, which can unintentionally lead to
health disparities. For example, crash test and CPR dummies are typically a male build78,79.
These disparities are further exacerbated when considering race and ethnicity. One way to
mitigate these biases and make healthcare more equitable is to have diverse representative
design teams.
Although many systemic issues can contribute to this gender/racial gap in the
workforce, one contributor is the lack of women and other historically marginalized
individuals choosing to major and graduate with a STEM degree. Although women
outnumber men on the many college campuses, they make up only 36% of graduates with a
STEM degree. Literature suggests that this is partly due to developing and maintaining a
STEM identity80.
STEM identity is one’s ability to acknowledge their knowledge and contribution to
STEM and has a sense of belonging in the field81. It can be influenced by many things such
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as educational experiences, representative role models, parental and societal expectations,
and STEM self-efficacy82,83. Self-efficacy is a well-established term used in education and
psychology literature to describe how well one believes one can complete a certain task84. It
can be influenced by experiences in the classroom, especially negative ones, as historically
marginalized communities are typically more sensitive to failures. One way to mitigate the
gender and racial gap in STEM is to recruit and retain more females and other marginalized
individuals by creating more inclusive classroom environments.
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CHAPTER THREE
AIM ONE: TEST THE EFFECTS OF SEX AND 17 Β-ESTRADIOL ON CARDIAC
FIBROBLAST MORPHOLOGY AND SIGNALING ACTIVITIES IN VITRO
3.1 Introduction
The prevalence of heart failure (HF) continues to rise, currently afflicting over 6.2
million Americans in roughly equal proportions among men and women1,2. What is not
equal is the diagnosis, prognosis, treatment, and overall understanding of HF on the basis of
biological sex2–5. Female data are underrepresented in animal studies and clinical trials, so
recommended treatment is not sex-specific, and adverse drug reactions occur at double the
rate in females than in males4. Notably, premenopausal females have a relative protection
against HF compared to age-matched males which subsides after menopause2,6. This
phenomenon has been studied extensively and is largely thought to be because of the
ovarian hormone estrogen3,4,7. Hormone replacement therapy (HRT) to maintain estrogen
levels in postmenopausal females was even considered cardioprotective for several
decades8,9. However, following randomized clinical studies, HRT was shown to have
overall adverse trends, increasing the risk of stroke, breast cancer, and heart attack in
postmenopausal females, and is not recommended for long-term use or as a preventive
measure for cardiovascular diseases6,8.
Although complete HRT is not a viable option to treat or prevent cardiac
pathologies, 17-β estradiol (E2) has exhibited promise in reducing cardiac fibrosis - an
accumulation of collagens and other extracellular matrix components that reduces pump and
electrical function7,10–12. After an initial myocardial infarction, a fibrotic response is
necessary to maintain structural stability but can continue uncontrolled resulting in chronic
HF13. There are currently no FDA-approved therapeutics to specifically target and control
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cardiac fibrosis13. In many in vitro studies, E2 treatment has been linked to a decreased
fibrotic response of cardiac fibroblasts (CFs), indicating its potential as a therapeutic10–12,14–
16

. It is important to note, many of these studies were done with neonatal rat CFs, pooling

male and female cells together, so sex-specific effects of estrogen treatment were, for the
most part, not investigated. Understanding how estrogen interacts with male and female
cells at the molecular level is imperative in order to leverage estrogen’s therapeutic effects
while minimizing potential adverse responses.
The few studies that do use sex-disaggregated analysis at the cellular level, nearly all
used tissue culture plastic (TCP) as the experimental platform. TCP has a stiffness that is
magnitudes higher than physiologic conditions, even a fibrotic environment. CFs are
extremely sensitive to their microenvironment, and when cultured on stiff substrates, many
proteins become activated due to mechanotransduction pathways that can make cells
profibrotic17–19. Additionally, a recent in vivo study by the Pinto group demonstrated the sex
dimorphic response of the regulation of several genes within CFs due to angiotensin II
stimulation20. Furthering our understanding of the intrinsic differences between male and
female CFs under physiologically “healthy” conditions is a necessary first step to
understanding the divergence of their intricate signaling pathways related to fibrosis. A
substrate stiffness of 8kPa was chosen for experiments because it is comparable to the
stiffness of healthy myocardium and has been used to mimic a non-fibrotic environment in
several other studies21–25.
Expanding our knowledge of how estrogen interacts with both male and female CFs
could aid in the discovery of novel treatment options for cardiac fibrosis that leverage
estrogen’s cardioprotective properties while mitigating its harmful effects. In this study, we
used cyclic immunofluorescence to investigate potential morphological changes, cellular
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localization, and activity levels of 12 proteins known to be heavily involved in estrogen
and/or profibrotic signaling within CFs. This allowed for a sex-disaggregated analysis of
not only each individual protein’s response to estrogen but also single-cell cross-correlation
analysis, which could uncover protein to protein crosstalk that could be potential sites to
target for regulation of cardiac fibrosis.
3.2. Materials and Methods
3.2.1 Cell Isolation and Culture
Adult Sprague Dawley rats (n=8 male: 8 wks, 265 grams; and n=8 female: 12 wks,
255 grams) were euthanized, and hearts were removed and collected in Krebs-Henseleit
buffer (Sigma, St. Louis, MO). All procedures were performed with approval from Clemson
University’s Institutional Animal Care and Use Committee. Ventricles were minced and
digested to isolate CFs according to previously reported protocols25,26. Liberase TM (Roche,
Indianapolis, IN) was used in each of the six successive enzymatic digestions at 37 C.
Supernatants from each digestion were collected and centrifuged at 300 g and 4 C and
resuspended in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma) containing 10%
fetal bovine serum (FBS, Atlanta Biologicals, Flowery Branch, GA), 100 U/mL penicillin
G, 100 µg/mL streptomycin, and 1 ng/mL amphotericin B (all Sigma). Following isolation,
cells were plated in T-25 culture flasks and incubated at 37 C and 5% CO2 for 4 h, after
which media was changed and thereafter was changed every 72 h until the serum starvation.
3.2.2 Collagen Coated Culture Plates
Prior to cell plating, 8 kPa 24-well CytoSoft® plates (Advanced BioMatrix, San
Diego, CA) were coated with Telocol-3 bovine collagen (Advanced BioMatrix). Collagen
solution was made at a 1:30 ratio of Telocol-3 in Phosphate Buffered Saline (PBS, Sigma).
1 mL of solution was pipetted into each of the 24 wells and allowed to polymerize at room
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temperature for 1 h. Excess solution was removed, and the wells were washed with PBS
twice.
3.2.3 Estrogen Treatment
Male and female CFs were passaged one time (P1) with 0.25% trypsin (Fisher) at a
1:3 dilution before use in experiments. Once the CFs had reached ~75% confluence after
the first passage, DMEM containing 10% FBS was removed, and flasks were washed with
PBS. A 24 h serum starvation was started with phenol-free DMEM (Fisher) + 2 mM Lglutamine (Fisher) and 2.5% charcoal-stripped FBS (GE Health, Chicago, IL) incubated at
37 C and 5% CO2. After 24 h, CFs were passaged (P2) and plated onto the CytoSoft®
plates at 10,000 cells/well. CFs were divided into 4 experimental groups across two
conditions: male vs. female and with or without 17-β Estradiol (E2, Sigma). The 24-well
plates allowed for two biological replicates with three technical replicates (wells) per
experimental condition. All wells were filled with 1 mL of phenol-free DMEM + 2 mM Lglutamine and 10% charcoal-stripped FBS. E2 was dissolved in ethanol at 10 mM, and 10
nM of E2 was added to wells designated for E2 treatment. An ethanol vehicle control of 10
nM was used as a control for all non E2 treated wells. Plates were incubated at 37 C and 5%
CO2 for 24 h. Following incubation, all wells were fixed with 4% paraformaldehyde (PFA,
Sigma) for 30 mins and 99.9% methanol (Fisher) for 10 mins. Immediately after fixation,
plates were filled with PBS, wrapped in parafilm, and stored at 4 C until use in cyclic
immunofluorescence (CycIF).
3.2.4 Cyclic Immunofluorescence
Wells were washed with Odyssey blocking buffer (Fisher) for 1 h at room
temperature on a rocker prior to antibody staining. Antibodies were purchased for the
following proteins of interest: alpha-smooth muscle actin (α-SMA), filamentous actin (F42

Actin), mothers against decapentaplegic homolog 3 (SMAD3), myocardin-related
transcription factor (MRTF), nuclear factor of activated T Cells (NFAT), nuclear factor
kappa-light-chain-enhancer of activated B Cells (NF-kB), phosphorylated extracellular
signal-regulated kinase (p-ERK), phosphorylated focal adhesion kinase (p-FAK),
phosphorylated jun n-terminal kinase (p-JNK), phosphorylated protein kinase B (p-Akt),
phosphorylated p38 mitogen-activated protein kinase (p-p38), and rho-associated protein
kinase (ROCK). Each antibody was individually optimized to determine unique staining
dilutions and microscope gain, exposure, and light settings. Appendix A Table 1 outlines
where each antibody was purchased, Alexa Fluor conjugation, staining dilution, and
microscope settings for each protein of interest. The order of CycIF and protocol were
determined according to published recommendations27.
Four consecutive rounds of CycIF were conducted with three proteins of interest
each round: (1) p-p38, NFAT, SMAD3, (2) MRTF, ROCK1, NF-kB, (3) p-JNK, p-Akt, αSMA, and (4) F-Actin, p-ERK, p-FAK (Figure 3.1). Primary and Alexa Fluor conjugated
antibodies were applied and rocked overnight at 4 C. A secondary mouse-anti-rabbit IgG
PE-Cy7 antibody for SMAD3, NF-kB, α-SMAD, and p-FAK was applied for 1 h at room
temperature while rocking. A Hoechst nuclear stain was rocked for ten minutes at room
temperature for each Cyc-IF round. All wells were washed four times with PBS between
staining and imaging. Alexa Fluor light cubes GFP, TxRed, Cy7, and DAPI, were used for
rounds 1 and 4 of CycIF; RFP, Cy-5, Cy-7, and DAPI light cubes were used for rounds 2
and 3. The ThermoFisher Fluorescence Spectra Viewer was used to ensure minimal spectra
overlap between channels28. An EVOS fluorescent microscope at 10x objective was used to
take ten images per well, and beacons were saved to return to that position in consecutive
CycIF rounds. Following each round of imaging, fluorophore inactivation was achieved by
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treating with 4.5% H2O2 (Fisher) in PBS plus 25 mM NaOH (Sigma) for 2 h under an LED
light. Inactivation was confirmed visually with the EVOS before moving on to the next
round of CycIF. Wells were washed with PBS four times after destaining and before the
next round of CycIF. All images were saved as 8-bit TIFF files, which were imported into
CellProfilerTM for post-image processing29.

Figure 3.1. An example of a set of images for each of the proteins of interest for four rounds of
CycIF. GFP, TxRed, and Cy7 (green, orange, and red) light cubes were used in rounds 1 and 4. RFP,
Cy5, and Cy7 (yellow, pink, and red) light cubes were used in rounds 2 and 3. A Hoechst nuclear stain
and DAPI light cube (blue) were used for all rounds.

3.2.5 Post-Image Processing
In CellProfilerTM, the lower quartile intensity background was subtracted from each
image. Images from consecutive rounds of CycIF were aligned with each other to account
for small changes in the field of view that occurred over multiple rounds. The Hoechst
nuclear stain images were used to identify Primary Objects (the nuclei), which were then
used to identify Secondary Objects (cellular outlines) (Figure 3.2.a). Morphological
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measurements of the total cell area, nucleus area and location, and minor and major axis
lengths were measured for each cell. To account for errors in automated cell identification,
an upper bound of 10000 µm2 and a lower bound of 1000 µm2 was set for acceptable cell
areas. Integrated, mean, and median intensities were also recorded for each image channel
(protein).
3.2.6 Statistical Analysis
Nearly 20,000 cells (~5,000/experimental condition) were identified across the
images taken from the 8 male and female biological replicates and used to analyze
morphological and protein-level data. Cell density was calculated per image across
experimental conditions, and there was no significant difference in cell viability in regards
to sex or estrogen treatment (p>0.05, 3.2.b). The median cell/nucleus area and elongation
for each biological replicate were determined per experimental condition. To account for
variability in fluorescent intensity among biological and technical replicates, normalization
was conducted by dividing the channel (protein) intensity in each cell by the median of that
channel intensity from all the cells on the entire plate (1 plate = 2 male and 2 female
biological replicates). This allowed for comparison of relative protein levels across
experimental conditions. MATLAB’s anova2 function was used to run a two-way ANOVA
to determine if a statistically significant (α=0.05) difference existed between or within
groups of sex (male vs. female) and estrogen treatment (baseline and +E2). Box and
whisker plots which show the median, 25th, and 75th percentiles of the 8 biological
replicates per experimental condition were generated. When there were instances of
statistical significance it is denoted on the graph, and all p-values are reported in Appendix
A Table 2. Single-cell correlation coefficients for each protein-protein and proteinmorphology interaction were also calculated using MATLAB’s built-in corrcoef function.
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Figure 3.2. Sample CellProfilerTM outlines of nuclei (green) and cells (purple) (a). A two-way ANOVA
was used to determine if there was any significant interaction (α=0.05) between sex (male=blue &
female=black) and estrogen treatment (baseline=open dots to represent median of biological replicates
and +E2=closed dots) on cell viability. No significant difference existed within groups or interaction
between groups for the mean cells/cm2 for each image (b).

3.3 Results
3.3.1 Sex-disaggregated analysis of CF morphology
Microscopic image analysis demonstrated no change in cell area across experimental
conditions (p>0.05, Figure 3.3.a). Likewise, cell elongation (p>0.05, Figure 3.3.b), which
was calculated by determining each cell’s aspect ratio (major/minor axis), was also not
affected by sex or estrogen treatment. Nuclear area and aspect ratio were observed and
determined not to be dependent on sex or estrogen treatment (p>0.05, Figure 3.3.c-d). FActin and α-SMA’s relative protein concentrations (p>0.05, Figure 3.3.e-f) did not vary
among experimental conditions, indicating that under physiological conditions, the structure
and morphological presentation of male and female CFs do not differ significantly.
3.3.2 Relative levels of fibrotic related signaling proteins
Relative protein levels were determined by comparing normalized median cell
intensities for each protein of interest. p-ERK had a statistically significant interaction
between sex and E2 treatment, with the female baseline being higher than all other
experimental conditions (p<0.05, Figure 3.4.a). p-p38 and ROCK1 were found to be
statistically different due to sex, with male cells having higher levels of both p-p38 and
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ROCK1 in the baseline and E2 treated cells compared to female cells with or without E2
(p<0.05, Figure 3.4b-c). p-FAK showed a statistically significant downregulation of the
relative levels of p-FAK in both male and female cells when E2 was present (p<0.05, Figure
2.4.d). No statistically significant change existed across experimental conditions for the
relative protein levels of p-JNK and p-Akt (p>0.05, Figure 3.4e-h).
3.3.3 Nuclear localization of mechanosensitive proteins
Many profibrotic proteins in CFs are in their most activated form when they have
translocated to the nucleus, which allows them to act as transcription factors to influence
gene regulation. In our study, MRTF, NFAT, NF-κB, and SMAD3 are all most activated in
the nucleus. Therefore, instead of measuring their total cell intensity, we calculated the ratio
of the intensity within the nucleus vs. the cytoplasm (normalized mean nuclear intensity/
normalized mean cytoplasm intensity). While MRTF, NFAT, NF-κB, and SMAD3 all had
ratios greater than 1 for each experimental condition indicating that more was present in the
nucleus than in the cytoplasm, only the levels of NFAT were different across experimental
groups (p>0.05, Figure 3.5.a-c). Male cells had NFAT levels in the nucleus that were higher
than both the baseline and E2 treated female cells (p<0.05, Figure 3.5.d).
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Figure 3.3. A two-way ANOVA was used to determine if there was any significant interaction (α=0.05)
between sex and estrogen on morphological factors. No significant difference existed within groups or
interaction between groups for total cell area and elongation (a and b), nor nucleus area and elongation
(c and d). F-Actin and α-SMA relative protein levels did not significantly change between experimental
conditions (e and f).

3.3.4 Correlation analysis of protein-protein interactions
An advantage of cyclic-IF analysis for protein quantification is that it enables singlecell measurements, which can be tested for protein-protein and protein-morphology
relationships. The Pearson’s correlation coefficients of the normalized relative proteinprotein levels and protein-morphology interactions were calculated along with their
corresponding p-values. These data were used to create dot plots (Figure 3.6), which allow
for the comparison of changes in protein-protein/protein-morphology interactions between
experimental conditions. The most striking difference is that there was a much stronger
correlation of protein-protein interactions for female CFs treated with estrogen (indicated by
large orange and yellow dots) than for male CFs treated with estrogen. Similarly, male CFs
without E2 demonstrated several strong and significant correlations, which were dampened
in the presence of E2. Female CFs experienced similarly correlated relationships with and
without E2 treatment.
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Figure 3.4. A two-way ANOVA was used to determine if any significant interaction (α=0.05) existed
between sex and estrogen treatment on the normalized median intensity of profibrotic proteins. p-ERK
showed a significant interaction between sex and E2 treatment (p<0.05, a). The median intensity of
ROCK1 and p-p38 was significantly different due to biological sex (p<0.05, b and c). E2 treatment
caused a significant difference in median intensity for p-FAK (p<0.05, d). No significant interactions
between or within groups existed for p-JNK or p-AKT (p>0.05, e and f).
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Male +E2

Figure 3.5. A two-way ANOVA was used to determine if any significant interactions existed between
sex and estrogen treatment of translocation of profibrotic proteins to the nucleus. The median nucleus:
cytoplasm ratio of NFAT was significantly different due to biological sex (p<0.05, a). There were no
significant interactions between or within groups for NF-κB, SMAD3, or MRTF (p>0.05, b-d).

Figure 3.6. Dot plots of correlation coefficients and their corresponding p-values for analysis of proteinprotein and protein-morphology interactions.

3.4. Discussion
Although many studies note the phenotypic differences between male and female
cardiac fibroblasts, very few have investigated if these phenotypic changes result in
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observable morphological differences in cell size and elongation. At a macro level, male
and female morphology are dimorphic, with male hearts and their components, including
the left ventricle, often being larger than female hearts from the same species30,31. As
fibrosis progresses, CFs undergo morphological changes, elongating and covering a larger
area due to interactions with their changing microenvironment24. This can also cause
nuclear morphologic changes mediated by LINC19. To fully understand the differences in
how male and female CFs interact with and respond to changes in their mechanochemical
environment during fibrosis progression, it is necessary to know if any morphological
differences are present in physiologically “healthy” environments. Our results indicate that
on a stiffness that mimics physiological conditions, there are no changes in cell and nuclear
morphology due to sex and estrogen treatment. This indicates that while male and female
cells may be phenotypically different at an intracellular level, these changes are more likely
to present biochemically rather than structurally. Our finding of no significant difference in
α-SMA and F-Actin relative protein levels due to sex and estrogen treatment also supports
this theory, as elevated α-SMA and F-Actin levels are both indicative of increased cell
contractility which can cause changes in cell morphology32.
Of the 12 proteins investigated, NFAT, p-p38, and ROCK1 were found to be more
elevated in male cells than female cells regardless of E2 treatment. Each of these proteins is
typically more elevated in a profibrotic environment19. This indicates that even in a
physiologically “healthy” environment, male CFs may be more sensitive to chemical
changes and prone to fibrotic behavior than female CFs. Sex disaggregated literature of the
behavior of these proteins in relation to fibrosis in CFs is extremely sparse. One in vivo
mouse study found that female mice underwent p-38- induced ventricular hypertrophy and
mortality at a slower rate than male mice33. Future research should investigate potential
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intrinsic differences of NFAT, p-p38, ROCK1, and other downstream proteins in male and
female CFs to clarify the divergence of male and female signaling pathways. This could
support development of sex-specific prevention and treatment methods for cardiac fibrosis.
CFs are very susceptible to changes in their microenvironment. A major way they sense and
translate these signals within the cell is through integrins and adhesion receptors on the cell
membrane. One highly studied CF adhesion receptor is focal adhesion kinase (FAK), which
can be activated (p-FAK) by interactions with the extracellular matrix24. In numerous
studies, FAK inhibition has been shown to stop adverse cardiac remodeling 34,35. Our results
showed that upon treatment with E2, both male and female CFs had reduced expression of
p-FAK, indicating its promise as a potential regulation pathway that mimics estrogen’s
cardioprotective effect. To our knowledge, no other studies investigate the effect of estrogen
on FAK in cardiac fibroblasts. However, there are a few studies that demonstrate how E2
treatment can actually activate FAK in breast cancer cells36,37. The microenvironment of a
breast cancer tumor is likely much stiffer than the 8kPa physiological like stiffness used in
our study, so it is possible that there is a complex interaction of mechanical cues and
hormone signaling, which affect FAK activation. FAK has many proteins downstream of it,
which are also considered profibrotic factors, so FAK’s pathways are a promising source of
potential regulation if more research is conducted to understand its response to combined
estrogen treatment and mechanical stimulus.
Not all of our proteins of interest had statistically significant differences between
experimental conditions (SMAD3, NF-κB, p-JNK, and p-Akt). This finding was slightly
surprising in regards to SMAD3 and p-JNK, because of past literature that cites the ability
of estrogen to downregulate SMAD3 and p-JNK activity in CFs7. These contradictory
findings are not unusual - a recent review of the limited research of sex differences and
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estrogen signaling in CFs notes additional discrepancies among various other peer-reviewed
studies 7. There are many differences in experimental setup, including in vivo vs. in vitro
design, pooled male and female cells vs. sex-disaggregated analysis, and neonatal vs. adult
cells. Our study adds an additional variable, substrate stiffness. Nearly all previous in vitro
studies of sex or estrogen signaling in CFs were done on TCP, which has an unrealistically
high stiffness (>1000 fold stiffer than myocardium). It is imperative to conduct further
sex/E2 focused studies within CFs controlling for individual variables before it is possible
to synthesize the results from multiple studies into a broader understanding of sex-specific
and estrogen-induced signaling in CFs.
In our study, the only protein of interest that had a statistically significant interaction
between sex and E2 treatment was p-ERK. Baseline levels of p-ERK in female CFs were
higher than in any other experimental condition; however, upon E2 treatment, female CFs
had levels similar to male CFs. There was a negligible difference between male baseline
and male +E2 relative protein levels of p-ERK. We hypothesize that this difference among
experimental conditions may related be to β-Adrenergic receptors (β-ARs), which are
believed to increase fibrotic activity through ERK(1/2) related pathways38. Many studies
have observed crosstalk in β-ARs and estrogen signaling39. Additionally, a recent study
outlined the sex dimorphic response in CFs due to β-AR stimulation40. As β-blockers are
already an FDA-approved treatment for many cardiovascular pathologies, including high
blood pressure and heart failure, this connection offers a promising avenue of potential
regulation of uncontrolled fibrosis that warrants further investigation.
Limitations of our study include that it was simply an in vitro monolayer culture
analysis with a serum starvation used to induce the baseline lack of estrogen condition. In
the future, enhanced in vitro platforms that utilize (1) a coculture of the multiple cell types
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present in the myocardium, (2) a 3D cell culture platform such as hydrogels, (3) and
applying cyclic stretch could all be used to better mimic a healthy cardiac environment25,41–
46

. We also want to acknowledge that α-SMA expression remained elevated in our cells

during the short experimental period. This is likely due to mechanical memory wherein cells
become activated during initial plating on TCP and then maintain some of that activity even
after reseeding onto softer substrates47. Future studies will either be conducted for a longer
time course or cultured on softer substrates immediately after cell isolation. Additionally, an
in vivo study with OVX mice could be used to truly mimic the changes in estrogen levels
due to menopause and other differences that are difficult to capture with an in vitro
platform. We also chose to use immunofluorescence to capture any potential morphological
and nuclear translocation of profibrotic factors intrinsic to male and female CFs with and
without estrogen treatment. Our analysis indicated that no significant structural differences
existed between male and female CFs on a physiologically similar stiffness of 8kPa, and
only NFAT expressed different levels of translocation to the nucleus among experimental
conditions. In future research, we would recommend that analysis could be done with
methods that could allow for a more robust signaling analysis, such as flow cytometry,
western blotting, or RNA-seq.
A more robust data set would provide the opportunity to conduct in silico
experiments, which could further elucidate our understanding of the complex signaling
networks of CFs. Our study was primarily focused on how mechanically activated signaling
pathways in CFs are impacted by estrogen and biological sex. There are other profibrotic
and proinflammatory pathways (i.e., DAMPs) in CFs independent of mechanical
stimulation that may be affected by biological sex and/or estrogen, which warrant study48.
In addition, the downstream response to estrogen stimulation can be affected by the
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presence of estrogen receptors (ER-α, ER-β, and GPR30)49,50. Future studies should utilize a
sex-disaggregated analysis to uncover possible differences in estrogen receptor expression
and regulation under physiologically “healthy” conditions. A computational approach will
facilitate the synthesis of findings from many independent experiments into a network of
the complex interactions of cardiac fibroblast signaling.
3.5. Conclusions
Our results support existing literature that cites male and female CFs are sexually
dimorphic, even under physiologically “healthy” conditions, and should be treated as such
when designing experiments to allow for sex-disaggregated analysis to determine how
biological sex may be affecting response to treatment interventions. Future research could
be directed toward uncovering the complex signaling interactions related to biological sex,
E2, and profibrotic signaling pathways. One way to hasten this investigation could be
through the use of sex-specific computational disease models. Existing disease models such
as the signaling network model of cardiac fibroblasts’ response to mechano-chemo
signaling could be improved by incorporating biological sex and hormone pathways51,52.
Large-scale sex-specific network modeling could greatly accelerate the pace and reduce the
costs of identifying important interactions involved in the regulation of fibrosis rather than
trial and error experiments alone.
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CHAPTER FOUR
AIM TWO: SCREEN FOR SEX-SPECIFIC DRUG EFFECTS IN A FIBROBLAST
NETWORK MODEL INTEGRATED WITH ESTROGEN SIGNALING
4.1 Introduction
Heart failure (HF) currently afflicts roughly 6.2 million Americans and has a fiveyear survival rate of only 50%1. Cardiac fibrosis, the uncontrolled accumulation of ECM
proteins, can exacerbate the progression of HF2–4. This deposition of ECM proteins is
crucial to a patient’s initial survival of myocardial infarction (MI) to form the scar tissue
that maintains the structural stability of the infarct region5. However, when it continues
uncontrolled, it becomes pathologic by reducing ejection fraction via thickening of the left
ventricle wall and causing a greater chance of arrhythmia due to disruptions in electrical
stimulus caused by collagen buildup6,7.
The current treatment regimen for patients suffering from HF includes drugs such as
angiotensin-converting enzyme (ACE) inhibitors and beta-blockers to reduce their blood
pressure and slow their heart rate, which reduces stress on the heart in an attempt to slow
the progression of HF8. However, no current FDA-approved treatments directly target
cardiac fibrosis9. Ongoing research focuses on developing a drug to directly inhibit cardiac
fibrosis or even reverse it10. Despite gains in understanding the complex signaling networks
of cardiac fibroblasts- the drivers of cardiac fibrosis- like most drug development, it is
expensive, slow going, and often found to have low efficacy rates upon clinical trials11.
The use of the computational models to conduct in silico experiments has been used
in a variety of ways to accelerate drug discovery12–15. Currently, these models are limited in
scope and, at best, can narrow down a pool of potential drug candidates for further study.
As the field of precision medicine grows, it is likely that the accuracy and predictive power
60

of these models will also improve. However, in order to fully leverage the predictive power
of these models, it is imperative that the data used to create them is robust. Unfortunately,
experimental studies and clinical trials are historically skewed to male data. For several
decades women of childbearing age were banned from participating in clinical trials16. Even
after this ban was reversed in the early 90s, it was not until 2016 that the NIH required the
use of both male and female animals in preclinical studies17. This has resulted in several
FDA-approved drugs having double the adverse drug response (ADR) rate in women.
Biological sex is an essential factor when considering cardiovascular health18–21.
Most notably, premenopausal females are less likely to suffer from MI compared to agematched men-primarily thought to be due to the cardioprotective role of the ovarian
hormone estrogen (E2)19. However, these discrepancies in cardiovascular health are not just
the result of hormones; there has also been research to show that genetic sexual
dimorphisms can also contribute to cardiovascular disease presentation and severity22.
Additionally, the literature suggests that many ADRs in both males and females occur in a
sex-specific manner23. Including sex hormones into computational models could help
correct for the dearth of sex-disaggregated studies available in the literature and make
precision medicine more accurate for patients.
In this study, we aim to make a previously published signaling network model of
cardiac fibroblasts sex-specific by incorporating E2. We then conducted a sex disaggregated
drug screen to analyze divergences in drug response between males and females.
4.2 Methods
4.2.1 Integration of estrogen into cardiac fibroblasts signaling network
A previously published signaling network model (SNM) of cardiac fibroblast was
expanded to include the ovarian hormone estrogen (E2). The previous model was created
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via a manual literature search of ~300 papers and included 109 nodes (i.e., proteins,
integrins, cellular receptors, and transcription factors) and 174 edges (reactions)24,25.
Specifically, this model was comprised of 11 biochemical and biomechanical inputs,
including transforming growth factor beta (TGFβ), angiotensin II (AngII), endothelin 1 (ET
1), and tension; downstream reactions of these inputs culminated in 22 cellular outputs,
including alpha-smooth muscle actin (α-SMA), procollagen I & III (proCI and proCIII),
several pro-matrix metalloproteinases and tissue inhibitors of metalloproteinases (proMMPs
and TIMPs), and proliferation. New nodes and/or reactions were added to the SNM if two
independent studies reported activation of inhibition of another node downstream of
estrogen signaling. At least one of these two papers used for model advancement was from
experiments conducted with cardiac fibroblasts; the second paper, if not from cardiac
fibroblasts, typically reported results from experiments from other cardiac or fibroblast cell
types. Nearly all of the papers used for model updates used neonate rat cardiac fibroblasts,
pooling male and female cells together, as their cell type.
As previously described, the reactions of the SNM are governed by logic-based
ODEs modeled as a system of Hill equations to capture node activity level24–26. Logical
NOT, AND, and OR gates were used for inhibitory and complex signaling interactions by
applying logical operations: fINHIB(x)= 1- f(x), fand(x1, x2) = f(x1)f(x2), and for(x1,x2) =
f(x1)+f(x2) - f(x1)f(x2). Differential equations were constructed using the open-source
software Netflux (https://github.com/saucermanlab/Netflux) for MATLAB (Mathworks,
Natwick, MA)27. Cytoscape was used to create all SNM visualizations included in this
paper28. All additional validation, perturbation, and drug screen simulations were conducted
using MATLAB; finalized codes used in the analysis will be made available on
SysMechBioLab GitHub (https://github.com/SysMechBioLab).
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4.2.2 Sex-Specific Model Creation
Sex-specific models were created by varying the weighting of the three estrogen
receptors added to the model to mimic the physiological difference of varied expression and
activity levels of estrogen receptors in male and female cells29. The reactions of E2 to the
three estrogen receptors were weighted as 0.5 (50% of maximum stimulation) and 1 (100%
of maximum stimulation in the male and female SNM respectively. Additionally, a pooled
SNM with a weighting of 0.75 for E2 stimulation of the three receptors was created to
validate studies conducted with pooled male and female neonate cells.
4.2.3 Model Validation
Previous model validation of the cardiac fibroblast SNM conducted with 47
independent papers of direct measurement of model intermediate and output nodes found
the SNM to be 81.8% accurate in predicting experimental activity levels of input-outputs
(i.e., AngII treatment on proCIoutput) and input-intermediates (i.e., AngII treatment out
ERK activity level) found in the literature24. In total these 47 papers accounted for 120
perturbations of input-outputs/intermediates validated by comparing literature experimental
results to model predictions according to their change in activity level as ‘Upregulation’ (Δ
Activity ≥5%), ‘Downregulation (Δ Activity ≤ -5%), or ‘No Change’ ( -5% < Δ Activity <
5%). Of these 120 perturbation experiments, 29 were counted in pooled neonates, 46 in
male cells, and 41 cell sex was unreported; no paper used in prior validation reported results
in a sex-disaggregated manner than included female data, and validation was not done in a
sex-desegregated manner.
To conduct a sex-desegregated validation of the updated model, 6 new papers were
added to the validation set to account for estrogen and female-specific data. Each of the
papers used for validation measured direct output secretion or intermediate signaling
63

response (i.e., ELISA, Western Blot, or PCR) to a single input stimulus in fibroblasts.
Validation perturbations were grouped by experiments reporting results in pooled neonates,
male, and female cells. Prediction accuracy was calculated using the same Δ Activity
bounds described above using either the pooled, male, or female SNM. Model simulation
predictions were generated in MATLAB as previously described (simulating basal
conditions for 80 hrs, followed by simulating single input stimuli (w=0.9) for 240 hr,
tension weight= 0.6)24. Ideal EC50 and n values were determined for each SNM through
multiple perturbations (Appendix C).
As the validation set was comprised of studies conducted on TCP, an additional
validation was conducted to compare model predictions to the results of my Aim 1 study
conducted on 8 kPa gels with both male and female cells. All parameters were kept
consistent with the above validation simulation, except a tension weight of 0.1 was used
instead of 0.6 to mimic the lower stiffness.
Additional validation was conducted to determine the accuracy of estrogen
involvement in signaling pathways by comparing a combination of simultaneous treatments
to experimental results. A tension weight of 0.6 and dosing weights of 0.9 for AngII, ET 1,
and E2 were simulated to compare experimental results from Pedram et al. that reported E2
effect on AngII and ET 1 stimulation on α-SMA, fibronectin, proCI, and proCII in pooled
neonate cardiac fibroblasts30. A negative control simulation of input weights of 0.1 was
generated by simulating basal conditions for 80 hrs, followed by simulating the treatment
conditions (AngII, ET-1, AngII + E2, ET-1 +E2, and E2) for an additional 240 hrs.
4.2.4 Network Perturbation Analysis
A network perturbation analysis was conducted in MATLAB as previously
described to identify influential signaling nodes under different estrogen conditions24. The
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input reaction weight of estrogen was attenuated, and all other input weights were kept at
0.1 for 80 hrs to simulate basal conditions. A Ymax=0.1 knockdown of individual nodes for
240 hrs was used to identify sensitive nodes by calculating Δ Activity for each node as the
sum of all knockdown simulation activity subtracted by basal conditions. Three perturbation
conditions were conducted: 1) male (male SNM, E2 input w=0.25), 2) female postmenopausal (female SNM, E2 input w=0.25), and 3) female pre-menopausal (female SNM,
E2 input w=0.9). Heat maps of the total knockdown effect on the SNM nodes were created,
as well as heat maps of the top ten influential and sensitive nods.
4.2.5 Drug Screen
A drug screen was applied to the cardiac fibroblast model as previously described12.
In this prior study, 121 drugs were identified from DrugBank to connect with nodes in the
model, totaling 36 unique drug-target interactions12,31. A sex-specific drug screen was
conducted using the same three experimental conditions used for the perturbation analysis
(male, female post-menopausal, and female pre-menopausal). A static application of drug
administration (w=0.85) on individual and paired profibrotic stimuli (w=0.6) for each of the
three experimental conditions. The effect of these simulations on proCI, EDFAN, α-SMA,
and MMPs was measured.
4.3 Results
4.3.1 Integration of estrogen into cardiac fibroblasts signaling network
We expanded the model to integrate E2 into the previously published model of
cardiac fibroblast signaling via a manual literature search of over 20 peer-reviewed
manuscripts to add 23 nodes and 29 edges (Figure 4.1). In addition, 6 already present
reactions were altered to include direct estrogen receptor inhibition activity. The nodes
added include E2 and its three primary receptors: estrogen receptor alpha (ERα), estrogen
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receptor beta (ERβ), and g-protein coupled receptor (GPR30)29,32. Additionally, cyclin beta
1 (Cyclinβ1) and cyclin-dependent kinase 1 (CDK1) were added downstream of GPR30 as
they were not already included in the fibroblast SNM33. The total network now consists of
132 nodes and 203 edges. The complete model, including all species (nodes), reactions, and
default parameter settings, can be found in Appendix B. In summary default parameter
settings included: reaction weights (w) as normalized activity levels between 0-1, Hill
coefficient (n)=1.25, EC50=0.6, yint=0, ymax=1, and time constant (τ)= 1, 0.1, or 10 for
signaling reactions, transcription reactions, and translation reactions respectively.

Figure 4.1. The updated SNM integrated with estrogen (E2) and its three receptors.

4.3.2 Model accuracy remains high after integration of E2
Accuracy of the model was maintained after the integration of E2 in the SNM.
When compared with 53 independent studies, 77% (94/122 simulations) of model
predictions matched results in the literature. Model predictions of estrogen treatment
specifically were 88% (15/17 simulations) accurate across experimental conditions. To
assess if model accuracy was influenced by sex, a sex-disaggregated analysis was
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conducted (Figs. 4.2 and 4.3) using the sex-specific SNMs for model simulations compared
with sex-disaggregated reporting in the literature. Model predictions were the most accurate
for the male SNM (81%, 46/57 simulations) and least accurate for the female SNM (67%,
2/3 simulations). The pooled SNM was 74% accurate (46/62 simulations). It is important to
note that the female SNM model validation was only conducted with 3 simulations and
compared with 2 papers. This is because very few papers report female-specific data for
cardiac fibroblasts.
For the most part, E2 stimulation without any other profibrotic stimulation (besides
tension) has relatively little effect on cellular signaling activity, which the model accurately
predicted. However, the model was accurate in predicting the divergent effect of estrogen
treatment on male and female proCI and proCIII production, with E2 treatment increasing
collagen production in males and decreasing it in females34. Additionally, the inclusion of
E2 into the model did not impact the accuracy of model predictions for other major cellular
inputs, including AngII and TGFB. The lower accuracy of the model in predicting
interleukin 1 (IL1), interleukin 6 (IL6), and neutrophil elastase (NE) effect on cellular
outputs is consistent with the previously published SNM’s limitations35.
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Figure 4.2. Model validation of the pooled neonate SNM created by altering weighting of estrogen
stimulation of its three receptors.
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Figure 4.3. Model validation of male (A), and female (B) SNMs created by altering weighting of
estrogen stimulation of its three receptors.
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4.3.3 Model is accurate in predicting cellular outputs in varied experimental contexts
The experiments used in the validation set were nearly all on an analysis of a
singular stimulus on cardiac fibroblasts plated on tissue culture plastic (TCP). To determine
if the models were accurate in predicting outcomes in various experimental contexts, model
predictions were validated against results from two additional peer-reviewed studies. The
first, Watts et al., were the results from my first aim in which I measured the effect of
estrogen on male and female cardiac fibroblasts plated on a soft stiffness of 8 kPa36. The
male and female SNMs were used to conduct sex-specific predictions of E2 treatment on
the 12 proteins of interest (Fig. 4.4). In total, the model was 79% accurate in matching the
experimental findings from my first aim. These results, combined with the validation set
above, provide evidence to support that E2 alone has a relatively limited effect on
downstream signaling activities within cardiac fibroblasts. However, when E2 treatment is
combined with fibrotic agonists effect on downstream signaling is more pronounced.

Figure 4.4. Model predictions compared to results of Watts et al. of the effect of estrogen treatment on
male and female cardiac fibroblasts plated on an 8kPa substrate36.
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Additionally, the model was validated by a paper from Pedram et al. that
investigated the effect of estrogen in conjunction with the fibrotic agonists AngII and ET 1
on pooled neonate cardiac fibroblasts (Fig 4.4)30. The model predictions were consistent
with in vitro results of the study, accurately predicting an increase in α-SMA, fibronectin,
collagen 1, and collagen II production when stimulated with AngII or ET 1. Likewise, when
these fibrotic agonists are paired with E2, the model predicts a return to control level values
of the measured outputs. E2 treatment alone also produced similar outcomes to control level
predictions similar to experimental results. The effect of E2 on collagen 1 and collagen III
was slightly more extreme in our model predictions than experimentally overserved outputs.

Figure 4.5. Model validation of the effect of estrogen (E2) in conjunction with fibrotic agonists. E2
maintained (or reduced) levels of the profibrotic cellular outputs in the model similar to in vitro
findings30.

4.3.3 Perturbation Analysis
The role of estrogen in cardiac fibroblast signaling is poorly understood, especially
in a sex-disaggregated context. A perturbation analysis was conducted to computationally
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uncover the downstream effect of estrogen treatment on a variety of experimental
conditions (Fig. 4.5). These conditions had input weights of 0.6 of all 10 fibrotic agonists’
model inputs. The male and female post-menopausal condition had an estrogen input weight
of 0.25, and the female pre-menopausal condition had an estrogen input weight of 0.9. The
top ten influential and sensitive nodes were also calculated for each condition. There were
many shared top influential nodes among each condition (tensionin, AT1R, ROS, NOX, and
AKT). Only the male SNM had P13K and NFKB as top influential nodes. In addition to the
top influential nodes the female SNM simulations shared with the male SNM, the female
conditions also shared E2 as expected. Only the female post-menopausal condition had CBP
and GPR30 as top influential nodes. The female pre-menopausal condition has ERB, ERX,
and PKA as unique top influential nodes. There were no shared top sensitive nodes among
all experimental conditions, indicating many points of divergences in downstream signaling
activity.

Figure 4.6. Perturbation analysis of downstream signaling activities due to estrogen treatment.
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4.3.4 Drug Simulation
A sex-disaggregated drug screen was conducted by dosing with 36 unique drug
targets (Appendix D) connected to nodes in the model (Fig. 4.7). The effect of the drugs on
fibrotic factors was analyzed when stimulated with various input stimuli with the same
experimental conditions used in the perturbation analysis. The most apparent impact is that
in the female pre-menopausal condition, the drugs’ effects on the model outputs of interests
(proCI, proliferation, EDFAN, proMMPs 1, 2, and 9) were significantly reduced. This is
likely because E2 is playing a cardioprotective role that is overshadowing the effect of the
drugs. The differences between the male condition and the female post-menopausal
conditions are much more subtle. In several cases (i.e., drugs targeting TNFα), it appears
that the up and down regulatory intensity of the drugs are influenced in a sex-specific
manner. There are only a few instances in which the drug has an entirely opposite effect in
the male vs. female post-menopausal screen. A notable example is the effect of drugs
targeting BAR and IL1RI on MMP1 that have been stimulated with TGFB and ET 1.
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Figure 4.7. Sex-specific drug screen of 36 unique targets for male, female post-menopausal, and female
pre-menopausal conditions.

4.4 Discussion
Developing a therapeutic to target and inhibit cardiac fibrosis has remained elusive
due to the complex signaling mechanisms of cardiac fibroblasts, which can be influenced by
biochemical factors, mechanical forces, and cellular sex. Very few studies investigate the
combined effect of all three of these influences on cardiac fibroblast signaling. In this study,
we aimed to develop sex-specific signaling network models (SNMs) of cardiac fibroblasts
by integrating estrogen signaling into a previously published SNM of cardiac fibroblasts to
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understand sex-specific divergences in fibrotic signaling networks. Additionally, we
conducted a sex-specific drug screen to determine if we could make sex-specific treatment
recommendations for cardiac fibrosis.
Integration of estrogen into the SNM did not negatively alter its previously high
predictive power in simulating experiments from the literature. Unsurprisingly, the male
SNM was the most accurate as the previously published versions of the model were built
and validated using experiments from papers that were overwhelmingly conducted using
only male cells25,35. It was difficult to fully validate the accuracy of the female SNM as
almost no studies report the effect of fibrotic agonists on female cardiac fibroblasts outside
the context of estrogen. Therefore, it was difficult to fully assess if the female SNM
accurately predicted the effect of the other model inputs such as AngII and TGFB on
outputs and intermediates. In the future, we recommend sex-disaggregated reporting to help
fill in the gaps of our understanding of sex-specific fibrotic signaling.
The results of the perturbation analysis uncovered potential regulatory nodes that
warrant further study. Two nodes that were in the top influencers of the male SNM and the
female post menopause SNM were NOX and mTORC2. However, in the female premenopause SNM, these nodes do not make the list as top influencers, indicating that at
higher estrogen levels, their effects are dampened. Neither NOX nor mTORC2 was directly
involved in reactions that were added or adjusted when integrating estrogen into the model.
Inhibition of NOX has been linked to decreases in collagen deposition37. Likewise,
mTORC2 has been reported to play a role in cellular contractility38. Targeting NOX and
mTORC2 could be a way to mimic the cardioprotective effect of E2 signaling.
The sex-disaggregated drug screen clearly exhibited the cardioprotective role of E2
in the female pre-menopause SNM. However, the differences between the male and female
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post-menopause SNMs were much more subtle. Although there were slight differences in
the intensity of the effect of the drugs in up or downregulating fibrotic factors in a sexspecific manner, the results did not provide enough evidence to elucidate mechanisms that
account for the ADRs that are more likely to occur in females compared to men. It is
possible that the integration of estrogen signaling alone was not enough to account for the
sex-specific differences in fibrotic response to different therapeutics. Future studies could
address this by integrating genomic or transcriptomic data into the model to account for
additional differences due to biological sex in addition to gonadal hormones.
4.5 Limitations and Future Directions
Many of the limitations of the sex-specific models designed in this study are due to
the lack of sex-specific data, particularly female data, available to build and validate the
model with, as discussed above. An additional major limitation of the current models is
their lack of quantitative data to infer input parameter values. Without these inputs, the
models can only make semiquantitative predictions that can be qualitatively compared to
experimental literature but have little clinical significance. Because of this constraint, the
model was only validated with estrogen levels of high (pre-menopausal) and low (male and
post-menopausal). However, like other hormones, estrogen levels can fluctuate from person
to person and throughout life. These attenuations were not accounted for and would likely
play a role in the downstream signaling response. Future studies could address this by
testing with more levels of estrogen and integrating feedback loops for estrogen and its
receptors.
4.6 Conclusion
We were able to successfully integrate estrogen signaling into a cardiac fibroblast
SNM in order to make sex-specific models of cardiac fibrosis. These models were validated
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to be ~80% accurate in predicting experimental outcomes from the literature, making it a
valuable tool to further study the sex dimorphisms in cardiac fibroblasts signaling caused by
estrogen. Estrogen’s cardioprotective effects were evident in the drug screen of the premenopausal SNM. Nuanced differences between the male and female premenopausal
conditions perturbation analysis and drug screen indicate several potential regulatory
mechanisms that warrant further study. Future research should focus on incorporating more
sex-specific data into the model itself and validation set to further enhance its capabilities in
making sex-specific predictions related to cardiac fibrosis.
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CHAPTER FIVE
AIM THREE: DEVELOPMENT OF SYSTEMS BIOLOGY EDUCATION MODULES
UTILIZING INCLUSIVE PEDAGOGY STRATEGIES
5.1 Introduction
In my first two aims, I investigated how biological sex affected the development of
cardiac fibrosis and discussed the need for further research due to the poor understanding of
sex as a biological variable. I intentionally framed my analysis around only biological sex
and not gender because I was primarily focused on the cellular level. However, at the macro
level, gender and biological sex can intersect to result in additional health disparities. The
male body has been historically considered the “standard,” and technologies are designed as
one size fits all to accommodate it. This has resulted in surgical tools being developed for
larger hands, crash test and CPR dummies having a male build, and the first FDA-approved
artificial hearts being too large for the average female patient1–3. These biases are likely due
partly to the lack of representation in the workforce, which also contributes to healthcare
inequities due to race and ethnicity. For example, recently, software designed to identify
skin cancer was found to only be accurate for those with white skin4. One way to mitigate
these biases and make healthcare more equitable is to have diverse representative design
teams.
Women and racial and ethnic minorities remain underrepresented in science,
technology, engineering, and math (STEM). On average, women make up roughly 50% of
the population and hold only a fraction of the engineering and computer workforce jobs
(15% and 25%, respectively)5. Likewise, historically marginalized communities, including
Blacks/African Americans, Hispanics/Latinos, and American Indians, collectively make up
about 31% of the US workforce but only 20% of STEM jobs5. Not only are these gender
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and racial/ethnic gaps leading to inequitable designs, but they are also limiting the ability of
the US to compete in the global science and engineering market6. Having an increased
number of women and racial and ethnic minorities enter the workforce would allow the US
to keep pace with the growing number of STEM jobs and lead to more productive and
creative teams that create equitable technology7,8.
To achieve a more diverse STEM workforce, the recruitment and retention of these
historically marginalized communities in postsecondary education will also need to
increase. Although women outnumber men on college campuses, they are less likely to
major and graduate with STEM degrees9. Likewise, Black and Latinx students who have
declared a STEM major are more likely to change majors or drop out than their White
peers10. These trends are often attributed to the formation of STEM identity, which can be
influenced by numerous factors, including middle and high school preparation, societal
expectations and stereotypes, university and workplace culture, representative role models,
and STEM self-efficacy11,12. Many informal education and mentoring programs have been
created to target underrepresented individuals in an attempt to counteract negative
influences and increase STEM identity. However, trends have remained relatively stagnant
or even dropped over recent years, indicating that more research needs to address the gender
and racial/ethnic gap in STEM13.
Recently the lens has turned to pedagogy and how creating a more inclusive
classroom environment can foster STEM identity in previously marginalized
communities14. It is well established that nearly all students benefit from a more active
learning environment than traditional lectures15,16. These techniques allow students to learn
by doing rather than passively listening. Literature has shown that in a classroom that
utilizes active learning techniques, students are less likely to fail the course, which in turn,
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can lead to higher rates of retention rates17,18. However, even in settings that utilize some
active learning techniques such as flipped classrooms and problem-based learning, there can
still be additional barriers that impact student performance. For example, in computational
classes, previous coding experience can be a predictor of perceived self-efficacy throughout
the course19,20. This affects those from under-resourced schools and others (like women and
racial/ethnic minorities) who do not typically partake in such activities even if they were an
option.
To address the growing need for computational skills in the workforce and higher
education, computational thinking and literacy have become part of the core curriculum in
recent years. Because the majority of K-12 teachers do not have a lot of previous coding
experience, researchers and practitioners have been investigating the use of unplugged
activities to facilitate the teaching of computational skills21,22. Unplugged activities facilitate
the learning of computational thinking skills through hands-on or role-playing activities in
lieu of technology or coding22–24. This technique has been shown to be effective in
increasing the computational literacy of primary school students, but little research has been
done on how this technique can also benefit older students with limited prior coding
experience to increase their self-efficacy in computational methods24. Using unplugged
activities in conjunction with traditional coding in computational settings could help level
the playing field for previously marginalized communities.
Additionally, it is well established that representative role models can increase
STEM self-efficacy for students from underrepresented populations. However, little
research has been done on how representative problem statements (i.e., gender or racespecific) in problem-based learning could also increase self-efficacy. Framing problems as
gender or race specific to target underrepresented student populations may provide them
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with additional motivation and interest and increase their STEM self-efficacy and identity
formation.
Problem-based learning is often paired with team-based learning in STEM
classrooms as a powerful tool to increase motivation and overall learning gains25,26.
However, this presents issues for marginalized communities. Stereotypes can be leveraged
against them, and task allocation for the technical aspects of a project is not always equal27.
We are interested in studying if representative problem statements (i.e., gender or racespecific) would also impact team dynamics such as task allocation, team interactions, team
contributions, and having relevant knowledge, skills, and abilities by providing students
from underrepresented populations with the additional agency to take the lead.
This work focuses on the development of computational biology education modules
designed to promote an inclusive learning environment by (1) utilizing a hybrid of
unplugged activities with coded simulation and (2) a female-oriented problem statement.
Additionally, I will discuss plans to investigate these interventions’ effects on STEM selfefficacy and team dynamics. Our research questions are:
1. What effect does pairing unplugged learning activities with traditional coding have
on the computational literacy of high school students?
2. To what extent does a female-centered computational biology problem statement
impact high school girls' STEM self-efficacy and identity?
3. How are team dynamics such as task allocation and contribution affected when
working on a female-focused problem?
5.2 Module Development
5.2.1 Module Development
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We have created five systems biology education modules for high school students
focused on various physiological processes and diseases. These modules will be piloted in
collaboration with Clemson’s Emerging Scholars program in July 2022. All modules
include three major components:
•

Unplugged Activities: To advance computational thinking and ease students and
teachers into modeling, the lesson plans start with a short active learning activity to
provide a hands-on or role-playing approach to the phenomena being modeled (i.e.,
a modified card game to model uncontrolled tumor growth). Each lesson plan also
includes recommended discussion questions to connect the unplugged activity with
computational concepts.

•

Computational Model Tutorial: Following the unplugged activity, students will
work through a guided tutorial to model the biological or disease phenomena. This
tutorial is designed to be conducted on a chrome book or similar device with the
open-source software NetLogo (see Figure 5.1)28. NetLogo was chosen as the
platform for model development because of its use of drag and drop coding paired
with traditional script coding, which we believe is best for our target audience of
high school students with limited previous coding experience.

•

Computational Model Advancement: The last component of our educational
modules is a deliverable in which students create their own virtual model by
modifying the model they created in the tutorial. The lesson plan provides guided
questions as suggestions for model improvement (e.g., What if the patient took a
drug that inhibited X, Y, or Z?) and encourages students to develop their own
questions. This last component allows educators to assess gains in their students’
computational abilities.
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Each of the five lesson plans created can be found in Appendix E. In addition to the
tutorial and model advancement questions given to students, each lesson plan contains an
overview page for instructors with learning objectives, definitions of applicable terms, a
time to complete estimation, and a guide to the unplugged activity with suggested follow-up
discussion questions. All modules are designed to be completed in 2-4 hours each. The
unplugged activities are intended to be completed in a group setting. The coding part of
each module could be completed individually or as a team. Because they are intended for
students with minimal coding experience, the modules build off each other and are
developed to be completed in sequence except for Modules 4 and 5, which cover very
similar computational concepts. Students will only complete either Module 4 or Module 5
in our pilot study, but in theory, they could complete both if they wanted extra practice on
independent module development. Completed NetLogo models can be found on the
Richardson Systems Mechanobiology Lab GitHub: (https://github.com/SysMechBioLab).
We plan to disseminate the modules publicly via journal publication after the completion of
the pilot study.

Figure 5.1. NetLogo interfaces with drag and drop buttons and coded script.

5.2.2 Modules Created
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All of the modules created are centered around common biological phenomena. The
first two modules build upon NetLogo’s built-in Tumor and Virus models to ease students
into the computational software. Modules 3-5 were independently created and require
students to develop a model from scratch (with a guided tutorial). The five modules
designed are detailed below and in Figure 5.2:
•

Tumor Growth: This module employs a built-in NetLogo ‘Tumor’ model as a way
to get students acclimated with the environment before asking them to code in it29. It
simulates a growing tumor and intervention techniques to stop the growth.
Biologically, students will observe the progression and treatment of a tumor from a
cellular level. Computationally, students will gain experience in using a model to
test predictions and identify model limitations. The unplugged activity tasks students
with playing a modified game of UNO, which simulates the behavior of the model
by showing how even if you are down to one card (i.e., a cancer cell), there is still
the possibility of regrowth. The model tutorial guides students through interacting
with the NetLogo interface. In the model advancement, students are asked to answer
questions about the model’s limitations and make suggestions for improvements.

•

Virus Prevention: This module modifies the built-in NetLogo ‘Virus’ model to
introduce additional parameters that model an intervention to slow the spread of a
virus within a population30. Biologically, students will examine population dynamics
and viral spread. Computationally, students will research and test the effect of input
parameters on a model. The unplugged activity guides students through a roleplaying game that uses logic comparable to the probability functions which guide
the simulation. In the model tutorial, students are shown how to introduce a new
variable to the model, ‘mask compliance.’ In the model advancement, students are
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asked to search the literature to find potential input parameters to model the spread
of a virus of their choosing.
•

Immune Reaction: This module will guide students through a tutorial to code a
NetLogo model from scratch that simulates an allergic reaction. Biologically,
students will consider how different cells and molecules interact to elicit an immune
response. Computationally, students will define rules and make assumptions to
create an agent-based model. The unplugged activity asks students to design the
rules for their own game, similar to how they will be defining rules for the
simulation. The model tutorial guides students in setting up the input parameters and
all of the agents needed for the model (e.g., mast cells, allergen, and histamines).
However, the tutorial does not end with a completed model; the agents do not
interact with each other. In the model advancement, students are tasked with
defining rules for their model and coding them to finish the simulation.

•

Gene Regulation: This module will guide students through a tutorial to code a
NetLogo model from scratch that uses Boolean Logic to create a simulation of the
lac operon genetic regulation system. Biologically, students will be exposed to a
standard model of gene regulation. Computationally, students will define rules using
Boolean logic and analyze model outputs to identify a system’s emergent
phenomena. The unplugged activity will lead students through a game of If and If
Else Simon Says as a way to familiarize them with Boolean logic. The model
tutorial will guide students through the beginning steps of creating a model with
many interactive parts from scratch. As this simulation is more challenging than the
other modules, students will work in teams during the model advancement to finish
the simulation and identify the model’s emergent phenomena.
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•

The Menstrual Cycle: This module will guide students through a tutorial to code a
NetLogo model from scratch that uses Boolean Logic to create a simulation of the
menstrual cycle. Biologically, students will be exposed to the hormones involved in
the menstrual cycle. Computationally, students will define rules using Boolean logic
and analyze model outputs to identify a system’s emergent phenomena. This module
was designed intentionally to mirror module 4 and will be used to test the use of a
female-focused problem statement vs. a generic problem statement on female selfefficacy and team dynamics. The unplugged activity, model tutorial, and model
advancement utilize similar concepts, and the end simulations are guided by similar
logic.

Figure 5.2. Five computational biology modules were created. All students will complete modules 1-3 in
sequence and then complete modules 4 or 5.

89

5.3 Plan to Pilot
5.3.1 Clemson’s Emerging Scholars Program
We plan to pilot the modules with the summer 2022 cohort of Clemson’s Emerging
Scholars program. This program invites rising high school sophomores-seniors from some
of South Carolina’s most under-resourced schools to Clemson’s campus for several weeks
to aid in college preparation. The program helps students prepare for their college
applications and has them take classes to expose them to different skills to prepare them for
college. I will be teaching a course on computational biology as part of this program from
July 6- 16, 2022, using the learning modules developed.
The students accepted in the Emerging Scholars program are most likely to be
female and or African American/Black, both of which are currently underrepresented in
STEM, providing an ideal population to study how the inclusive learning techniques
incorporated in the modules impact the self-efficacy team dynamics. We anticipate that
there will be about 60 students in the cohort this summer that will be divided up into three
classes of ~20 students. The course will be seven 1.5 hr sessions long per class. All research
will be conducted in accordance with Clemson’s IRB office and Protocol IRB2022-0059.
5.3.2 Quasi-Experimental Intervention
We will use a quasi-experimental approach to measure the effect of the modules on
students assigned to groups who either complete module 4 or module 31. All students will be
asked to complete modules 1-3 individually. For the final module, students will be split up
into a team of 4, with at least two female students per team. Half of the teams will be asked
to complete Module 4: Gene Regulation and Stability Using Boolean Logic; the other half
will be given Module 5: The Menstrual Cycle Using Boolean Logic. All teams may not be
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used in the analysis if there is an uneven number of students or not enough male and female
students.
5.3.3 Exit Survey
To measure any changes in self-efficacy, I will deploy an exit survey on the last day
of the program to all students. This survey will ask students to rate their pre-and postunderstanding of computational and biological concepts using a 1-10 Likert scale. The
concepts they will be rating will be taken from the learning objectives of the lesson plans. I
will conduct a sex-disaggregated analysis on whether there are similar self-efficacy changes
for individuals on teams who completed the lac operon or the menstrual cycle modules.
Additionally, the exit survey will ask students to rate their satisfaction with various
module components, including the unplugged module activities. There will also be openended questions to allow students to provide more depth to their answers. Results from the
exit survey will be used to (1) evaluate students’ overall satisfaction with the modules, (2)
determine if students believed the unplugged activities affected student their perceived selfefficacy in completing computational tasks, and (3) determine if a female-focused problem
affected student’s perceived self-efficacy in completing computational tasks. The exit
survey can be found in Appendix F.
5.3.4 CATME Survey
I will use the Purdue CATME survey to measure team dynamics, allowing students
to rate their teammates on various facets, including contributions, interactions, knowledge,
and skills32. This survey will be used to determine if a female-focused problem affected
team dynamics. The Purdue CATME survey can be found in Appendix G.
5.3.5 Interviews
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I will also conduct 5-10 follow-up interviews with students to ask them more indepth questions about their satisfaction with the modules, perceived self-efficacy, and team
dynamics. The sample interview protocol can be found in Figure 5.3.

Figure 5.3. Interview protocol that will be used with 5-10 students.

5.4 Conclusion
The learning modules developed allow for the teaching of computational techniques
through the use of unplugged activities paired with coded simulation. We anticipate that this
will enable students with limited prior computational experience to feel more comfortable
and able to complete tasks, thereby increasing their self-efficacy. A significant limitation of
our study is that while we hope these modules will improve recruitment and retention of
underrepresented students to STEM degrees and careers, we do not currently have plans to
run a longitudinal study to see if they have long-term effects. Additionally, we are only
conducting a one-week course as part of the pilot study. Future studies could investigate the
use of these pedagogies throughout a semester-long course and conduct follow-up studies
on major retention and degree attainment to truly determine the long-term effect of these
strategies.
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These modules could be a useful tool for practitioners who teach computational
courses at the high school or early college level who instruct students with varied coding
experience. Additionally, our analysis of the use of a female problem statement on female
self-efficacy and team dynamics will provide potential evidence of the efficacy of
representative problem statements targeted at underrepresented student populations. We
believe such problem statements could be developed to address a variety of contexts across
STEM disciplines and other fields to foster an inclusive learning environment.

93

References
1. Adams, D. M. et al. One size does not fit all: current disposable laparoscopic devices do
not fit the needs of female laparoscopic surgeons. Surg. Endosc. 22, 2310–2313 (2008).
2. Criado-Perez, C. Invisible women: data bias in a world designed for men. (Abrams
Press, 2019).
3. One Size Fits Few: Artificial Hearts Leave Many Out | Live Science.
https://www.livescience.com/52093-artificial-hearts-too-large-for-many-to-receive.html.
4. O’Neil, C. Weapons of Math Destruction: How Big Data Increases Inequality and
Threatens Democracy. (Crown, 2016).
5. Fry, R., Kennedy, B. & Funk, C. STEM Jobs See Uneven Progress in Increasing
Gender, Racial and Ethnic Diversity. Pew Research Center Science & Society
https://www.pewresearch.org/science/2021/04/01/stem-jobs-see-uneven-progress-inincreasing-gender-racial-and-ethnic-diversity/ (2021).
6. Varma, R. U.S. Science and Engineering Workforce: Underrepresentation of Women
and Minorities. Am. Behav. Sci. 62, 692–697 (2018).
7. Hong, L. & Page, S. E. Groups of diverse problem solvers can outperform groups of
high-ability problem solvers. Proc. Natl. Acad. Sci. 101, 16385–16389 (2004).
8. Freeman, R. B. & Huang, W. Collaboration: Strength in diversity. Nature 513, 305–305
(2014).
9. Hill, C., Corbett, C. & St. Rose, A. Why so few? women in science, technology,
engineering, and mathematics. (AAUW, 2010).
10. Riegle-Crumb, C., King, B. & Irizarry, Y. Does STEM Stand Out? Examining
Racial/Ethnic Gaps in Persistence Across Postsecondary Fields. Educ. Res. 48, 133–144
(2019).
11. Shapiro, C. A. & Sax, L. J. Major selection and persistence for women in STEM. New
Dir. Institutional Res. 2011, 5–18 (2011).
12. Henderson, J., Rangel, V. S., Holly, J., Greer, R. & Manuel, M. Enhancing Engineering
Identity Among Boys of Color. J. Pre-Coll. Eng. Educ. Res. J-PEER 11, (2021).
13. Colleges now produce fewer Black graduates in math and engineering. The Hechinger
Report http://hechingerreport.org/even-as-colleges-pledge-to-improve-share-of-engineeringgraduates-who-are-black-declines/ (2021).
14. Mills, J., Ayre, M. E. & Gill, J. Gender Inclusive Engineering Education. (Routledge,
2010). doi:10.4324/9780203851951.

94

15. Theobald, E. J. et al. Active learning narrows achievement gaps for underrepresented
students in undergraduate science, technology, engineering, and math. Proc. Natl. Acad.
Sci. U. S. A. 117, 6476–6483 (2020).
16. Active learning increases student performance in science, engineering, and
mathematics. PNAS https://www.pnas.org/doi/abs/10.1073/pnas.1319030111.
17. Freeman, S. et al. Active learning increases student performance in science,
engineering, and mathematics. Proc. Natl. Acad. Sci. 111, 8410–8415 (2014).
18. Kvam, P. H. The Effect of Active Learning Methods on Student Retention in
Engineering Statistics. Am. Stat. 54, 136–140 (2000).
19. Ramalingam, V., LaBelle, D. & Wiedenbeck, S. Self-efficacy and mental models in
learning to program. in Proceedings of the 9th annual SIGCSE conference on Innovation
and technology in computer science education - ITiCSE ’04 171 (ACM Press, 2004).
doi:10.1145/1007996.1008042.
20. Lewis, C. M., Yasuhara, K. & Anderson, R. E. Deciding to major in computer science:
a grounded theory of students’ self-assessment of ability. 8.
21. Harris, C. Computational Thinking Unplugged: Comparing the Impact on Confidence
and Competence from Analog and Digital Resources in Computer Science Professional
Development for Elementary Teachers. Educ. Dr. (2018).
22. Caeli, E. N. & Yadav, A. Unplugged Approaches to Computational Thinking: a
Historical Perspective. TechTrends 64, 29–36 (2020).
23. Rodriguez, B., Kennicutt, S., Rader, C. & Camp, T. Assessing Computational Thinking
in CS Unplugged Activities. in Proceedings of the 2017 ACM SIGCSE Technical
Symposium on Computer Science Education 501–506 (Association for Computing
Machinery, 2017). doi:10.1145/3017680.3017779.
24. Brackmann, C. P. et al. Development of Computational Thinking Skills through
Unplugged Activities in Primary School. in Proceedings of the 12th Workshop on Primary
and Secondary Computing Education 65–72 (Association for Computing Machinery, 2017).
doi:10.1145/3137065.3137069.
25. Leupen, S. Team-Based Learning in STEM and the Health Sciences. in Active Learning
in College Science: The Case for Evidence-Based Practice (eds. Mintzes, J. J. & Walter, E.
M.) 219–232 (Springer International Publishing, 2020). doi:10.1007/978-3-030-336004_15.
26. Hyams, J. H. & Raidal, S. L. Problem-Based Learning: Facilitating Multiple Small
Teams in a Large Group Setting. J. Vet. Med. Educ. 40, 282–287 (2013).
27. Fowler, R. R. & Su, M. P. Gendered Risks of Team-Based Learning: A Model of
Inequitable Task Allocation in Project-Based Learning. IEEE Trans. Educ. 61, 312–318
(2018).
95

28. NetLogo Home Page. http://ccl.northwestern.edu/netlogo/.
29. NetLogo Models Library: Tumor. https://ccl.northwestern.edu/netlogo/models/Tumor.
30. NetLogo Models Library: Virus. https://ccl.northwestern.edu/netlogo/models/Virus.
31. Gopalan, M., Rosinger, K. & Ahn, J. B. Use of Quasi-Experimental Research Designs
in Education Research: Growth, Promise, and Challenges. Rev. Res. Educ. 44, 218–243
(2020).
32. CATME Features. CATME https://info.catme.org/features/.

96

CHAPTER SIX
CONCLUSIONS, LIMITATIONS, AND FUTURE DIRECTIONS
6.1 Summary of Findings
Multiple strategies were used to address the gender data gap in healthcare. In Aims 1
and 2, I discussed the lack of female data and understanding of estrogen signaling in
relation to cardiac fibrosis. We found that the effects of sex and biological sex have a varied
impact on profibrotic factors in cardiac fibroblast. Although morphologically we did not
observe differences in a physiological stiffness of 8 kPa in vitro, different proteins reacted
in various ways to estrogen treatment occasionally in a sex-specific manner. When done in
silico, we were able to accurately integrate estrogen signaling into a previously created
signaling network model of cardiac fibroblasts to develop sex-specific models. After
perturbation analysis and drug screens with the sex-specific models, we were able to
identify several regulatory pathways that warrant further study to elucidate their
involvement in the sex dimorphisms of cardiovascular health. Finally, in Aim 3, five
systems biology education modules were developed with inclusive pedagogy strategies,
including unplugged activities and representative problem statements to target
underrepresented individuals. The plan to pilot these modules to investigate the effect on
STEM identity, self-efficacy, and team dynamics were also outlined. These in vitro, in
silico, and in classroom strategies could be further advanced by addressing some of their
significant limitations.
6.2 Study Limitations
6.2.1 Aim 1 Limitations
Limitations for Aim 1 include that it was an in vitro monolayer culture of
fibroblasts, only treated with estrogen (E2), alpha-smooth muscle actin (α-SMA) remained
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elevated, and that it was a limited analysis of protein-protein interactions. We used an in
vitro monolayer culture of cells for the experimental platform because we were primarily
interested in the effect of sex differences and E2 treatment on a physiological similar
stiffness. However, in the future, to further mimic physiological conditions, a coculture of
multiple cell types of the heart (i.e., cardiomyocytes) could be used1. Additionally, a 3-D
culture platform such as spheroids or hydrogels could be developed if a more advanced
analysis was desired2,3. Because the heart is an organ that dynamically beats, it could also
be interesting to apply cyclic stretch or mechanical stimulus to mimic this phenomenon in
vitro to investigate its effect on sex and E24. Estrogen is one of many gonadal hormones in
the body that play a role in cellular processes. In future experiments, other gonadal
hormones such as progesterone and testosterone could be dosed in addition to estrogen
when studying sex-specific effects. Additionally, in order to more accurately mimic
menopause, an in vivo study with ovariectomized (OVX) mice could be conducted5. An
unexpected result of Aim 1 was that α-SMA expression remained elevated even on 8 kPa
stiffness plates. This was surprising as there are other studies that report minimal to no αSMA expression on low stiffnesses6. Recent literature suggests that cells can maintain a
mechanical memory after being plated on tissue culture plastic (TCP). In the future, we
would recommend plating cells on softer substrates immediately after isolation when
conducting stiffness analyses or for conducting experiments for more extended time points
(as opposed to 24 hrs) to allow cells to get reacclimated to their new environment7. Finally,
in Aim 1, we only conducted a limited analysis of protein-protein interactions. This
limitation was addressed in Aim 2 with the fibroblast signaling network model.
6.2.2 Aim 2 Limitations
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A significant limitation of the sex-specific SNMs of cardiac fibrosis developed in
Aim 2 was that they have little physiological relevance in their current state. The models
would need to be updated with more robust input parameters in order to have quantifiable
outputs that could be used for diagnosis and treatment initiatives. Additionally, the female
SNM needs to be further validated. There were insufficient female-specific data in the
literature to provide a substantial validation set to ensure our confidence in the female SNM
model’s predictions. Finally, the results of the drug screen revealed very subtle differences
between the male and female post-menopausal conditions. It is likely that estrogen signaling
alone is not enough to account for the sex-specific trends in drug response and adverse
reactions, and in the inclusion of other biologically relevant factors such as genomics,
transcriptomics, or other hormones could added to future iterations of the model.
6.2.3 Aim 3 Limitations
A significant limitation of the learning modules developed in Aim 3 is that due to
the COVID-19 pandemic, our plans were postponed until summer 2022, so we do not have
any preliminary data on their efficacy and reception. Additionally, although our goal is that
the inclusive pedological strategies utilized in the module lesson plans will increase the
recruitment and retention of historically marginalized individuals to STEM fields, we do not
plan to conduct a longitudinal study to truly investigate the long-term effect of such
strategies. In the future, we would recommend integration of these strategies in a longer
time frame (i.e., a semester-long course) with follow-up studies to directly investigate the
effect on retention of underrepresented individuals.
6.3 Future Directions
As discussed throughout this manuscript, female data are widely underrepresented in
the literature and clinical trials, which are significant contributors to healthcare inequities.
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Although many funding agencies state they are now requiring the inclusion of female
samples to receive funding, this is not always reflected in studies that continued to be
published using only male samples. In the future, I believe journal editors and reviewers
could have one of the most significant influences the to make inclusion of female and/or
sex-disaggregated data an expectation, not just a bonus, of peer-reviewed studies.
Additionally, bootstring representation of women in STEM could help to increase the
studies which incorporate female samples into their studies.
The overarching goal of this dissertation was to address the gender data gap that
exists in healthcare through various strategies in and out of the lab. However, there are
many other contributors to healthcare inequities beyond the lack of female data.
Race/ethnicity, socioeconomic status, sexual orientation, and gender identity are all also
significantly understudied influences on the care patients receive. Additionally, although
they were often treated as a dichotomy throughout this dissertation, for many individuals,
sex and gender are on a spectrum that is not stagnant throughout life. These are all factors
that need to be adequately investigated and addressed, especially as precision medicine
techniques become more widely used to ensure that diagnostic and treatment interventions
are accurate for all patients.
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Appendix A
Table A1:

Table A2:

103

Appendix B
Species information
module
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
tension
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
growth factor
growth factor
growth factor
growth factor
growth factor
growth factor
growth factor
growth factor
growth factor
growth factor
growth factor
g-coupled
g-coupled
g-coupled
g-coupled
g-coupled
tension

ID
AngII
AngIIin
AngIIfb
AT1R
AGT
ACE
NOX
ROS
ET1
ET1in
ET1fb
ETAR
DAG
PKC
TRPC
NE
NEin
BAR
AC
cAMP
PKA
CREB
CBP
TGFB
TGFBin
TGFBfb
TGFB1R
smad3
smad7
latentTGFB
BAMBI
PDGF
PDGFin
PDGFR
NP
NPin
NPRA
cGMP
PKG
tension

name
Yinit Ymax
angiotensin II
0
ang II input
0
ang II feedback
0
angiotensin II receptor type 1
0
angiotensinogen
0
angiotensin converting enzym
0
NAD(P)H oxidase
0
reactive oxygen species
0
endothelin 1
0
endothelin 1 input
0
endothelin 1 feedback
0
endothelin 1 receptor A
0
diacyl-glycerol
0
protein kinase C
0
transient receptor potential ca
0
norepinephrine
0
norepinephrine input
0
beta adrenergic receptor 1 or
0
adenylate cyclase
0
cyclic adenosine monophosp
0
protein kinase A
0
cAMP response-element bind
0
CREB - binding protein
0
transforming growth factor b
0
transforming growth factor b
0
transforming growth factor b
0
TGFB receptor
0
small mothers against decape
0
0
TGFB1 with latent protein co
0
BMP and activin bound inhib
0
platelet derived growth factor
0
platelet derived growth factor
0
platelet derived growth factor
0
natriuretic peptide
0
natriuretic peptide input
0
natriuretic peptide receptor
0
cyclic guanosine monophosp
0
protein kinase G
0
membrane or adhesion tensio
0
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1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

tau

1
1
1
0.1
10
0.1
0.1
0.1
1
1
1
0.1
0.1
0.1
0.1
1
1
0.1
0.1
0.1
0.1
0.1
0.1
1
1
1
0.1
0.1
10
10
0.1
1
1
0.1
1
1
0.1
0.1
0.1
1

tension
tension
tension
tension
tension
tension
tension
tension
cytokine
cytokine
cytokine
cytokine
cytokine
cytokine
cytokine
cytokine
cytokine
cytokine
cytokine
cytokine
cytokine
cytokine
MAPK
MAPK
MAPK
MAPK
MAPK
MAPK
MAPK
MAPK
MAPK
MAPK
MAPK
MAPK
MAPK
MAPK
adhesion
g-coupled
adhesion
adhesion
growth
growth

tensionin
tensionfb
B1int
Rho
ROCK
Ca
calcineurin
NFAT
IL6
IL6in
IL6fb
gp130
STAT
IL1
IL1in
IL1RI
TNFa
TNFain
TNFaR
NFKB
PI3K
Akt
p38
TRAF
ASK1
MKK3
PP1
JNK
abl
Rac1
MEKK1
MKK4
ERK
Ras
Raf
MEK1
FAK
epac
Factin
FA
cmyc
CTGF

tension input
tension feedback
beta 1 integrin
a Rho-dependent GTPase
rho associated protein kinase
calcium
calcineurin
nuclear factor of activated Tinterleukin-6
interleukin-6 input
interleukin-6 feedback
IL-6 receptor complexed to g
signal transducers and activat
interleukin-1 alpha and beta
interleukin-1 input
IL1 receptor type I
tissue necrosis factor alpha
tissue necrosis factor alpha in
TNF alpha receptor
nuclear factor kappa-light-ch
phosphoinositide 3-kinase
protein kinase B
a MAP kinase
tnf receptor associated factor
apoptosis signal related kinas
mitogen activated protein kin
protein phosphatase 1
a MAP kinase
abl tyrosine kinase
a Rho-dependent GTPase
a MAP3K associated with p3
a MAP2K associated with p3
a MAP kinase
representing the family of GT
family of raf protein serine/th
a MAP2K mainly specific to
focal adhesion kinase
exchange protein activated by
polymerized actin
stabilization of focal adhesio
myc transcription factor
connective tissue growth fact
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0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

1
1
0.1
0.1
0.1
0.1
0.1
0.1
1
1
1
0.1
0.1
1
1
0.1
1
1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
1
1
0.1
0.1

growth
adhesion
ECM
adhesion
MAPK
ECM
ECM
ECM
ECM
ECM
ECM
ECM
ECM
ECM
ECM
ECM
tension
adhesion
MAPK
adhesion
tension
adhesion
adhesion
ECM
growth
growth
growth
growth
tension
ECM
ECM
ECM
ECM
ECM
tension
tension
tension
adhesion
adhesion
adhesion
adhesion
g-coupled

proliferation
SRF
EDAFN
aSMA
AP1
TIMP1
TIMP2
PAI1
proMMP14
proMMP1
proMMP2
proMMP9
fibronectin
periostin
proCI
proCIII
B3int
Src
Grb2
p130Cas
YAP
MRTF
Gactin
TNC
mTORC1
mTORC2
p70S6K
EBP1
syndecan4
proMMP3
proMMP8
proMMP12
thrombospon
osteopontin
contractility
RhoGEF
RhoGDI
talin
vinculin
paxillin
MLC
AT2R

proliferation
serum response factor
extra domain A of fibronectin
alpha-smooth muscle actin
activator protein 1
tissue inhibitor of metallopro
tissue inhibitor of metallopro
plasminogen activator inhibit
inactive MMP14
inactive MMP1
inactive MMP2
inactive MMP9
fibronectin
periostin
procollagen I
procollagen III
beta 3 integrin
proto-oncogene tyrosine-prot
growth factor receptor-bound
breast cancer anti-estrogen re
yes-associated protein 1
myocardin-related transcripti
monomeric actin
tenascin-c
mammalian target of rapamy
mammalian target of rapamy
p70-S6 kinase 1
eukaryotic translation initiati
syndecan 4
inactive MMP3
inactive MMP8
inactive MMP12
thrombospondin 4
osteopontin
intracellular tension
a Rho guanine nucleotide exc
a Rho GDP-dissociation inhi
talin 1
vinculin
paxillin
myosin regulatory light chain
angiotensin II receptor type 2
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0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

10
0.1
10
10
0.1
10
10
10
10
10
10
10
10
10
10
10
0.1
0.1
0.1
0.1
0.1
0.1
1
10
0.1
0.1
0.1
0.1
0.1
10
10
10
10
10
1
0.1
0.1
0.1
0.1
0.1
0.1
0.1

estrogen
estrogen
estrogen
estrogen
estrogen
estrogen
estrogen
ECM

E2
E2in
ERX
ERB
GPR30
CyclinB1
CDK1
LOX

17-beta estradiol (estrogen 2)
17-beta estradiol (estrogen 2)
estrogen receptor alpha
estrogen receptor beta
G protein-protein coupled est
cyclin beta 1
cyclin-dependant-kinase 1
lysyl oxidase
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0
0
0
0
0
0
0
0

1
1
1
1
1
1
1
1

1
1
0.1
0.1
0.1
0.1
0.1
10

Reaction Information
module ID
Rule
input
i1
=> AngIIin
input
i2
=> TGFBin
input
i3
=> tensionin
input
i4
=> IL6in
input
i5
=> IL1in
input
i6
=> TNFain
input
i7
=> NEin
input
i8
=> PDGFin
input
i9
=> ET1in
input
i10
=> NPin
input
i11
=> E2in
input
i12
AngIIin => AngII
input
i13
TGFBin => TGFB
input
i14
tensionin => tension
input
i15
IL6in => IL6
input
i16
IL1in => IL1
input
i17
TNFain => TNFa
input
i18
NEin => NE
input
i19
PDGFin => PDGF
input
i20
ET1in => ET1
input
i21
NPin => NP
input
i22
E2in => E2
middle r1
AngII & !ERB => AT1R
middle r2
AT1R => NOX
middle r3
NOX => ROS
middle r4
IL6 => gp130
middle r5
ROS => p38
middle r6
ROS => JNK
middle r7
IL1RI & !ERX => NFKB
middle r8
gp130 => STAT
middle r9
TNFaR => PI3K
middle r10
TGFB1R & !PKG & !smad7 & !ERB => smad3
middle r11
ERK & !ERX => NFKB
middle r12
p38 &!ERX => NFKB
middle r13
ETAR => ROS
middle r14
ERK => AP1
middle r15
cAMP => PKA
middle r16
!smad3 => CBP
middle r17
!CREB => CBP
middle r18
TGFB1R => ACE
middle r19
TGFB & !BAMBI => TGFB1R
middle r20
PKA => CREB
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Weight n EC50
0.1
1.25
0.1
1.25
0.1
1.25
0.1
1.25
0.1
1.25
0.1
1.25
0.1
1.25
0.1
1.25
0.1
1.25
0.1
1.25
0.1
1.25
1
1.01
1
1.01
1
1.01
1
1.01
1
1.01
1
1.01
1
1.01
1
1.01
1
1.01
1
1.01
1
1.01
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25
1
1.25

0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6

middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle

r21
r22
r23
r24
r25
r26
r27
r28
r29
r30
r31
r32
r33
r34
r35
r36
r37
r38
r39
r40
r41
r42
r43
r44
r45
r46
r47
r48
r49
r50
r51
r52
r53
r54
r55
r56
r57
r58
r59
r60
r61
r62
r63
r64

NE => BAR
ET1 => ETAR
IL1 => IL1RI
PDGF => PDGFR
BAR => AC
BAR & AT1R => AC
AC => cAMP
FAK =>MEKK1
cAMP => epac
Rho => ROCK
TNFa => TNFaR
NP => NPRA
NPRA => cGMP
cGMP => PKG
Ras => Raf
Raf & !ERK => MEK1
MEK1 & !PP1=> ERK
p38 => PP1
MKK3 => p38
TGFB1R => TRAF
Rac1 => MEKK1
MEKK1 => MKK4
MKK4 & !NFKB => JNK
PDGFR => abl
abl => Rac1
JNK => cmyc
TNFaR => TRAF
TRAF => ASK1
ASK1 => MKK3
ASK1 => MKK4
IL1RI => ASK1
Ras => p38
TGFB1R => PI3K
PDGFR => PI3K
FAK => PI3K
TGFB1R => NOX
Akt & !ERX => NFKB
JNK => AP1
IL1RI & TGFB => BAMBI
STAT => smad7
Rho & !Rac1 => p38
MKK4 & !Rho => JNK
TGFB1R => Rho
AT1R => Ras

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
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1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25

0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6

middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
middle

r65
r66
r67
r68
r69
r70
r71
r72
r73
r74
r75
r76
r77
r78
r79
r80
r81
r82
r83
r84
r85
r86
r87
r88
r89
r90
r91
r92
r93
r94
r95
r96
r97
r98
r99
r100
r101
r102
r103
r104
r105
r106
r107
r108
r109

ETAR => DAG
AT1R => DAG
DAG => TRPC
TRPC => Ca
Ca => calcineurin
calcineurin => NFAT
PDGFR => Src
Akt => mTORC1
mTORC1 => p70S6K
!mTORC1 => EBP1
Akt => smad3
!p70S6K => mTORC2
mTORC2 & PI3K => Akt
mTORC2 & DAG => PKC
AP1 & !YAP => smad7
AT1R => YAP
AngII => AT2R
ROS & !AT2R => ERK
tension => B1int
PKC & tension => B1int
tension & Src => p130Cas
tension => TRPC
tension => AT1R
B3int => Src
B1int => FAK
FAK & Src => Grb2
Grb2 => Ras
FAK & Src => RhoGEF
!Src => RhoGDI
FAK & Src => p130Cas
p130Cas & abl => Rac1
Factin => YAP
PKA => RhoGDI
RhoGEF & !RhoGDI & !PKG => Rho
syndecan4 => PKC
!PKC => RhoGDI
NFAT & !Gactin => MRTF
ROCK & Gactin => Factin
!Factin => Gactin
MRTF => SRF
FAK & Src & MLC => paxillin
B1int => talin
B3int => talin
vinculin & CDK1 & !paxillin => FA
ROCK => MLC
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1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25

0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6

middle
middle
middle
middle
middle
middle
middle
middle
middle
middle
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output
output

r110
r111
r112
r113
r114
r115
r116
r117
r118
r119
r120
r121
r122
r123
r124
r125
r126
r127
r128
r129
r130
r131
r132
r133
r134
r135
r136
r137
r138
r139
r140
r141
r142
r143
r144
r145
r146
r147
r148
r149
r150
r151
r152
r153

E2=> ERX
E2=> ERB
E2=> GPR30
ERB=> cAMP
ERB=> PKA
ERX=> Akt
!GPR30=> CyclinB1
CyclinB1 & AngII => CDK1
AT1R & !CDK1=>TGFB
GPR30=>Akt
CDK1=> proliferation
AP1 => proliferation
CREB => proliferation
CTGF => proliferation
PKC => proliferation
!EBP1 & p70S6K => proliferation
cmyc => proliferation
NFKB & AP1 & !smad3 => proMMP1
AP1 => proMMP2
STAT => proMMP2
STAT => proMMP9
AP1 & NFKB => proMMP9
AP1 => proMMP14
NFKB => proMMP14
NFKB & AP1 & !smad3 => proMMP8
NFKB & AP1 & !smad3 => proMMP3
CREB => proMMP12
AP1 => TIMP1
AP1 => TIMP2
smad3 => PAI1
YAP => PAI1
SRF => proCI
SRF => proCIII
smad3 & CBP & !epac=> proCI
smad3 & CBP & !epac=> proCIII
smad3 & CBP => fibronectin
NFKB => fibronectin
NFAT => EDAFN
smad3 & CBP => periostin
CREB & CBP => periostin
NFKB => TNC
MRTF => TNC
smad3 => thrombospondin4
AP1 => osteopontin
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1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25

0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6

output
output
output
output
output
output
fback
fback
fback
fback
fback
fback
fback
fback
fback
fback
fback
fback
fback
fback
fback
fback
fback
fback
fback
fback
fback
fback

r154
r155
r156
r157
r158
r159
r160
r161
r162
r163
r164
r165
r166
r167
r168
r169
r170
r171
r172
r173
r174
r175
r176
r177
r178
r179
r180
r181

smad3 & CBP & ERK => CTGF
YAP => CTGF
Akt => LOX
YAP => aSMA
smad3 & CBP => aSMA
SRF=> aSMA
AP1 => latentTGFB
proMMP9 & latentTGFB => TGFBfb
proMMP2 & latentTGFB => TGFBfb
tension & latentTGFB => TGFBfb
!AT1R & !JNK & p38 => AGT
ACE & AGT => AngIIfb
CREB + CBP => IL6fb
NFKB => IL6fb
AP1 => IL6fb
AP1 => ET1fb
Factin & MLC => contractility
aSMA & MLC => contractility
!thrombospondin4 & tension => B3int
osteopontin => B3int
!TNC & tension => syndecan4
talin & contractility => vinculin
contractility & FA => tensionfb
TGFBfb => TGFB
AngIIfb => AngII
IL6fb => IL6
ET1fb => ET1
tensionfb => tension

112

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0.25
0.25
0.25
0.25
0.25

1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.25
1.01
1.01
1.01
1.01
1.01

0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.5
0.5
0.5
0.5
0.5

Appendix C
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Appendix D
Drug name
Bosutinib
Dasatinib
Nilotinib
Ponatinib
Benazepril
Captopril
Cilazapril
Enalapril
Fosinopril
Lisinopril
Moexipril
Perindopril
Quinapril
Ramipril
Rescinnamine
Spirapril
Trandolapril
Arsenic trioxide
Azilsartan medoxomil
Candesartan
Eprosartan
Forasartan
Irbesartan
Olmesartan
Tasosartan
Telmisartan
Valsartan
Losartan
Saprisartan
A.T. Globulin
Arbutamine
Arformoterol
Bambuterol
Clenbuterol

Binding
Non-Competitive
Non-Competitive
Non-Competitive
Non-Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Non-Competitive
Non-Competitive
Non-Competitive
Competitive
Competitive
Competitive
Competitive
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Action
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Agonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Agonist
Agonist
Agonist
Agonist

Target
abl
abl
abl
abl
ACE
ACE
ACE
ACE
ACE
ACE
ACE
ACE
ACE
ACE
ACE
ACE
ACE
AP1; ERK
AT1R
AT1R
AT1R
AT1R
AT1R
AT1R
AT1R
AT1R
AT1R
AT1R
AT1R
B1int
BAR
BAR
BAR
BAR

Dipivefrin
Dobutamine
Droxidopa
Ephedra
Epinephrine
Fenoterol
Formoterol
Indacaterol
Isoetarine
Isoprenaline
Norepinephrine
Olodaterol
Orciprenaline
Pirbuterol
Procaterol
Ritodrine
Salbutamol
Salmeterol
Terbutaline
Vilanterol
Acebutolol
Alprenolol
Atenolol
Betaxolol
Bevantolol
Bisoprolol
Bopindolol
Bupranolol
Carteolol
Carvedilol
Celiprolol
Esmolol
Labetalol
Levobunolol
Metipranolol
Metoprolol
Nadolol

Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive

Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
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BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR
BAR

Nebivolol
Oxprenolol
Penbutolol
Pindolol
Practolol
Propranolol
Sotalol
Timolol
Amiodarone
Amyl Nitrite
Erythrityl Tetranitrate
Isosorbide Dinitrate
Nitroglycerin
Nitroprusside
Ocriplasmin
Ambrisentan
Bosentan
Maitentan
Sitaxentan
Tocilizumab
Canakinumab
Gallium nitrate
Anakinra
Siltuximab
Cobimetinib
Trametinib
Marimastat
Glucosamine
Triflusal
Thalidomide
Sacubitril
Entresto

Competitive
Competitive
Competitive
Competitive
Competitive
Competitive

Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist

BAR
BAR
BAR
BAR
BAR
BAR

Competitive
Competitive
Non-Competitive
Non-Competitive
Non-Competitive
Non-Competitive
Non-Competitive
Non-Competitive
Non-Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Non-Competitive
Competitive
Competitive
Competitive
Non-Competitive
Competitive

Antagonist
Antagonist
Antagonist
Agonist
Agonist
Agonist
Agonist
Agonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist

Non-Competitive
Non-Competitive
Non-Competitive
Non-Competitive
Competitive

Antagonist
Antagonist
Antagonist
Agonist
Both

BAR
BAR
BAR
cGMP
cGMP
cGMP
cGMP
cGMP
EDAFN
ETAR
ETAR
ETAR
ETAR
gp130
IL1
IL1
IL1R1
IL6
MEK1
MEK1
MMP1; MMP2; MMP9;
MMP14
MMP9
NFKB
NFKB; TNFa
NP
NPRA (Agonist); AT1R
(Antagonist)
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Urokinase
Becaplermin
Pazopanib
Sunitinib
Sorafenib
Regorafenib
Dabrafenib
Fasudil
Ripasudil
Galunisertib
Lucanix
Trabedersen
Adalimumab
Certolizumab pegol
Infliximab
Pomalidomide
Etanercept
Golimumab

Non-Competitive
Competitive
Non-Competitive
Non-Competitive
Non-Competitive
Non-Competitive
Non-Competitive
Competitive
Competitive
Non-Competitive
Competitive
Competitive
Non-Competitive
Non-Competitive
Non-Competitive
Non-Competitive
Competitive
Competitive
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Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist

PAI1
PDGFR
PDGFR
PDGFR
PDGFR; Raf
PDGFR; Raf; abl
Raf
ROCK
ROCK
TGFB1R
TGFBmRNA
TGFBmRNA
TNF
TNF
TNF
TNF
TNFa
TNFa

Appendix E

Module 1: Tumor Growth Simulation & Limitations

Platform: NetLogo
Following this lesson students should be able to:
1) Describe basic cancer cell metabolism and migration
2) Utilize NetLogo’s built-in sample models
3) Develop and test predictions of therapeutic targets using a tumor
model
4) Evaluate a model’s limitations
Purpose: This module employees a built-in NetLogo tumor model.
Biologically, students will observe the progression and treatment of a
disease from a cellular level. Computationally, students will gain
experience in using a model to test predictions as well as identifying
model limitations.
Biological Terms:
1) Tumor: an abnormal mass of cells
2) Cancer: the uncontrolled continues replication of cells
3) Apoptosis: programmed cell death
4) Metastasis: the spread of cancer cells to other parts of the body
5) Remission: the disappearance of the symptoms and signs of
cancer
Computational Terms:
1) Computational Model: a mathematical model used to study the
behavior of a complex system
2) Systems Biology: the modeling of complex biological systems
3) Limitations: refers to simplifications or missing details in a model
that make it unable to capture the full natural phenomena
4) Stem Cell: a term in the model referring to original cancer cells
(blue dots). Can replicate into more stem cells and transitory cells.
They also can metastasize
5) Transitory Cell: a term in the model referring to cells derived from
an original cancer stem cell (red dots). They can divide into more
cancer transitory cells but will slow (white dots) and undergo
apoptosis (black dots) after a few replications
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Time Estimation:
1) In-Class Activity: 30 minutes
2) Model Tutorial: 30 minutes
3) Model Testing and Advancement: 15 minutes
Total: ~1 hour 15 minutes
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Part One: In-Class Activity

Materials: UNO or standard card decks
Rules:
1) Split students into groups of ~4-8
2) Have only half the number of students play at first and the others
observe
3) Have them play UNO as normal
4) After two minutes, have students give green cards (split evenly) to
spectating students who draw an additional 5 cards and join the
game (models migration and formation of secondary tumor)
5) Keep playing UNO as normal
6) After two more minutes, have students discard any card that is an
even number (models a treatment of killing transitory cells)
7) Have them keep playing as normal
8) After two more minutes, have all students draw a card. If a student
draws a yellow card then they no longer have to draw cards if they
don’t have a move for the remainder of the game (models a
treatment of killing stem cells)
9) Have them keep playing for an additional five-ten minutes or until
the game is over
10) Discuss observations in small groups or as a class
Modification for Individual Activity: A single student can deal out hands
for all “participants” with cards face-up, then proceed through steps
above while playing all hands.
Modification for standard card deck: The game should be easily modified
for a standard deck of cards by changing the rules to use suits instead of
colors and assigning typical UNO rules like “draw 4” or “skip” to face
cards.
Suggested Discussion Questions:
1) Did the students who benefited from the “treatments” run out of
cards faster?
2) How is UNO a good model of cancer metabolism and migration?
3) How is UNO NOT a good model of cancer metabolism and
migration (i.e. what were the limitations)?
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1)
2)
3)
4)
5)

Part Two: Model Tutorial

Open NetLogo
Under File choose Model Library
Choose Tumor under Biology>Evolution
Click Setup button
Click Go button and watch as the model very quickly expands into
a large original tumor and a smaller metastasized tumor. Also note
that the graph almost immediately levels off. To stop the model, hit
Go again
6) Adjust the speed bar so that it is slower (very far left)
7) Click the Setup button again to reset the model and run it again by
clicking Go
a. What type of relationship does the graph appear to have
now?

8) Play around with the interventions (Kill Transitory Cells, Kill
Moving Stem Cell, and Kill Original Stem Cell).
a. What happens when you Kill Original Stem Cell immediately
(before first replication)?

b. What happens when you Kill Original Stem Cell before the
tumor has metastasized?

c. What happens when you Kill Original Stem Cell after the
tumor has metastasized?

d. What happens when you Kill Transitory Cell immediately
(before first replication)?
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e. What happens when you Kill Transitory Cell before the
tumor has metastasized?

f. What happens when you Kill Transitory Cell after the tumor
has metastasized?

g. What happens when you Kill Moving Stem Cell immediately
(before first replication)?

h. What happens when you Kill Moving Stem Cell before the
tumor has metastasized?

i. What happens when you Kill Moving Stem Cell after the
tumor has metastasized?

j. All three interventions achieved remission if applied before
the first replication, why is this likely not a feasible treatment
option?
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k. If you could only apply one intervention, which do you think
offers the best chance of remission? Does this depend on
whether the tumor has metastasized already?
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Part Three: Model Testing and Advancement:

1) Using your analyses from step 8, predict the best combined
treatment (i.e. (1) Kill Transitory Cells and Original Stem Cell, (2)
Kill Transitory Cell and Moving Stem Cell, or (3) Kill Moving Stem
Cell and Original Stem Cell) for a tumor that has already
metastasized.
a. Prediction:

2) Test your prediction with the model.
a. Did your treatment achieve remission? Explain.

3) Because this model is extremely basic, it has many limitations
which make it unlikely to ever to be used to decide an actual
treatment plan.
a. In your opinion, what are the model’s three biggest
limitations?

b. Choose one of these limitations and describe what you
think should be added to the model to address this
limitation.
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Module 2: Virus Prevention Simulation and Model Inputs

Platform: NetLogo
Following this lesson students should be able to:
1) Describe the factors that can impact a virus’s spread throughout a
population
2) Modify a given Netlogo model by adding and deleting buttons from
the main interface
3) Research the literature to supply model with input parameters from
published experimental data
4) Determine what additional rules and/or variables should be added
to a model to address its limitations
Purpose: This module modifies the built-in NetLogo Virus code to
introduce additional parameters that model an intervention to slow the
spread of a virus within a population. Biologically, students will examine
population dynamics and viral spread. Computationally, students will
research and test the effect of input parameters on a model.
Biological Terms:
1) Virus: a microorganism that can only reproduce by infecting living
cells
2) Infectiousness: the likelihood (probability) that a contagious
disease will be transmitted from one person to another
3) Transmission: the act of spreading a disease, like a virus, form
organism to another
4) Immunity: the ability of an organism to fight off an infection. After
an organism has survived an initial infection of a virus, they often
have immunity from that same virus for a long period of time
Computational Terms:
1) Agents: beings in a model that can follow given instructions
2) Turtles: agents in NetLogo that can move around in the world
3) Patches: agents in NetLogo that make up the 2-D space turtles
move around on
4) Parameters: a variable included in a model that can be estimated
from data
5) Buttons: a feature in NetLogo which allows the user to adjust
parameters without manipulating the code
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Time Estimation:
1) In-Class Activity: 30 minutes
2) Model Tutorial: 30 minutes
3) Model Testing and Advancement: 1 hour
Total: ~2 hours
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Module 2: In-Class Activity

Materials: Dice, meter stick, and note cards or stickers to identify
different student groups
Rules:
1) Split the students up into 4 groups in an area where they can walk
around but not so big that they will be too spread out
2) Let each group decide input parameters for their group:
a. Define how many people should be in each subgroup to
start: Sick-Unmasked ____, Sick-Masked ____, HealthyMasked ____, Healthy-Unmasked ____
b. Define how close in feet students need to be for it to be
considered “close contact” ____
c. Define the infection rate for Mask-Mask contact (i.e. roll a
two= 1/6) ____ and Mask-Unmask contact (i.e. roll any even
number= 1/2) ____ if one of the individuals is sick
3) Have one group perform their simulation at a time while the other
groups observe
4) For each simulation, have students walk around randomly and
stop them after five seconds
5) If there is a healthy and sick student within the decided distance
have each close contact roll a die to determine if the virus will
spread
6) Repeat steps 3-4 one more time and tell students who were sick to
start with that they are now immune and cannot get sick again
7) Repeat steps 3-5, remembering to tell students they are immune
after two cycles until all students are either healthy or immune
8) Repeat steps 4-7 for the remaining three groups
9) Discuss observations in small groups or as a class
Modification for Individual Activity: A single student can cut out small
squares of paper, label one side of each square “healthy” (or a smiling
face), and the other side “infected” (or a frowning face, virus picture,
etc.). Proceed through the steps above.
Suggested Discussion Questions:
1) Which input parameter do you think would have had the greatest
effect?
2) Did each group’s simulation take about the same about of time to
finish? Why or why not?
3) What are some limitations of this model? Would adding/changing
any of the input parameters address these limitations?
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1)
2)
3)
4)
5)
6)

Part Two: Model Tutorial

Open NetLogo
Under File choose Model Library
Choose Virus under Biology>Evolution
Click Setup button
Click Go button and observe
To stop the model, hit Go again. This module explains how a virus
can spread through a population, but it is not detailed enough to
exhibit or test how we could slow or stop the spread of a virus.
One proven way to slow the spread of most viruses is to wear
masks. This is something Asian countries have been doing for
years, but something that did not become popular in the U.S. until
the COVID-19 outbreak of 2020
7) Download the Virus_Mask text file. This file has been modified to
include variables that allow for the testing of how mask
compliance in a population can influence the spread of an
infectious disease
8) Copy the text from the file and paste it into the code of the Virus
module
9) Navigate back to the main interface, you will likely get an error
message that says certain variables have not been defined which
is what we will do in the next few steps
10) Right click on the button that says Turtle Shape and delete the box
11) Press the Button drop down box near the top of the screen and
choose a Slider to add by clicking on an open area under the
sliders already in the interface
12) In the pop-up menu, name the global variable infectiousness-mask
and change the units to %. Hint: Make sure to type this and later
variable names exactly because it directly refers to the code
13) Repeat step 10 but call this global variable mask-compliance and
also change the units to %
14) Repeat step 10 but call this global variable sick-people and also
change the units to %. You should now have 7 sliders (numberpeople, infectiousness, chance-recover, duration, infectiousnessmask, mask-compliance, and sick-people) which allow you to
manually adjust the model input parameters
15) Under Tools, choose Turtles Shapes Editors
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16) Scroll down to Person and click Duplicate
17) Name the person mask-person
18) Use the shape tools to draw a mask on the person and click Okay
when finished
19) Exit out of the Turtles Shapes Editors
20) Click Setup, there should no longer be any errors and many
figures should pop up in the black model screen some of whom
are healthy (green) and some that are sick (red). The starting
amount of people can be adjusted with the slider number-people.
Some of the people should also be wearing masks, the percentage
of people wearing a mask can be adjusted with the maskcompliance slider
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Part Three: Model Testing and Advancement

1) One important consideration when making a model is to use data
from the literature for input parameters to increase its accuracy.
Choose a virus and look-up values for infectiousness (likelihood of
transmission without mask), infectiousness-mask (likelihood of
transmission with mask), chance-recover (survival rate), and
duration (average length of infection). Good resources for this
include: https://www.cdc.gov/ or https://pubmed.ncbi.nlm.nih.gov/

a.

What values did you find?
Infectiousness:
Infectiousness mask:
Chance recover:
Duration:
2) Incorporate these values into the model by using the sliders
3) Now, make a hypothesis about the percentage of mask-compliance
that would be necessary to eliminate the virus in exactly 6 months
(0.5 years) if 25% (sick-people) of the population was already
infected. Hint: To make observation easier, you may need to adjust
the speed of the model with the speed slider at the top of the
interface
a. Hypothesis:

4) Test your prediction by running the model until the infection rate
reaches 0%.
a. Did you ever reach 0% infection?

b. How long did it take to reach 0% infection?

c. If it did not take exactly 6 months, try adjusting your
prediction for mask-compliance and repeat the model test
until you get closer to six months. Explain your adjustments
and outcomes.
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5) The main rule governing this model is that if a sick turtle is on the
same patch as another turtle it determines if the other turtle is (1)
sick (2) immune and (3) wearing a mask. If the turtle is already sick
or immune, nothing happens. If the other turtle is not sick or
immune already, it will determine if the turtle is wearing a mask
and a random number between 0-100 will be generated and if this
number is less than the infectiousness rate set by the user for
each scenario, the other turtle will get sick.
The code for this is:

A major limitation of this rule is that it does not consider if the sick
turtle is wearing a mask; the infection rate is solely decided by if
the other non-sick turtle is wearing a mask.
a. What other parameters and rules would have to be added to
the model to address this limitation? Either describe in
words or attempt a coded notation of what should be added.

6) This model is extremely basic and has many limitations which
make it unlikely to ever to be used to decide an intervention plan
a. In your opinion, besides the one mentioned above what are
the model’s three biggest limitations? Hint: you might
discuss other interventions to slow a virus’s spread besides
just wearing masks that the current model fails to consider.
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b. Choose one of these limitations and describe what you think
should be added to the model to address this limitation.
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Module 3: Immune Reaction Simulation Rules

Platform: NetLogo
Following this lesson students should be able to:
1) Describe the body’s immune response due to an allergen
2) Define rules for agents of a model given a biological phenomenon
3) Code simple rules/commands using NetLogo
4) Evaluate how assumptions can increase a model’s limitations
Purpose: This module will guide students through a tutorial to code a
NetLogo model from scratch that simulates an allergic reaction.
Biologically, students will consider how different cells and molecules
interact to elicit an immune response. Computationally, students will
define rules and make assumptions to create an agent-based model.
Biological Terms:
1) Allergen: a substance that when ingested or inhaled can elicit an
immune response
2) Antibody: a ‘Y’ shaped protein that recognizes specific antigen
such as an allergen
3) Immunoglobulin E (IgE): the type of antibody produced by the body
after the first encounter with an allergen that will recognize it again
4) Mast Cells: are coated with IgEs which will recognize a second
encounter with an allergen and cause the mast cell to release
granules such as histamines
5) Histamine: a compound that can interact with white blood cells and
proteins to cause symptoms of an allergic reaction such as itching
or sneezing
Computational Terms:
1) Agent-based model: a type of modeling governed by agents that
have been given a set of rules
2) Rules: the instructions given to an agent that defines its decisionmaking process
3) Assumptions: user-determined simplifications that are intended to
decrease the complexity of a model
4) Command: a term used in programming to indicate a coded
instruction for a program or model to carry out
5) Breed: a term in NetLogo to define an agent set with distinguished
characteristics (i.e. size, shape, color, and rules) from other turtles
in the simulation
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Time Estimation:
1) In-Class Activity: 30 minutes
2) Model Tutorial: 1 hour
3) Model Testing and Advancement: 1 hour 30 minutes
Total: 3 hours
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Part One: Unplugged Activity

Materials: multicolored beads
Rules:
1) Split students into groups of ~4-5
2) Give each group a bag of multi-colored beads and have them
devise their own activity to model an allergic reaction using the
beads. Have students define rules for the activity making sure to
define what would cause a reaction (e.g., picking a yellow bead), a
reaction response (e.g., do ten jumping jacks), and what will end
the activity (e.g., everyone picks 5 beads).
3) Have students conduct their activities in their groups while the
other groups observe
4) Discuss as a class
Suggested Discussion Questions:
4) What different rules did students come up with?
5) Were there certain rules that worked “better” than others to model
an allergic reaction?
6) Were there any groups that were not able to conduct their activity
smoothly because they did have enough rules (or too many)?
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Part Two: Model Tutorial

1) Open NetLogo
2) Instead of using one of the built-in codes, you will be making one
from scratch today. Click the Code tab to get started
3) Define the three breeds of variables that will be part of the model:
allergens, mast cells, and histamines using breed [plural_form
singular_form]

4) To set up the simulation, make a command called to setup. Under
the command, type 4 actions (1) clear-all, which will clear all
variables each time the code is run (2) reset-ticks, which will
initialize the time to be 0 (3) set-mast-cells, a command which will
initialize the mast-cells on the main interface (4) set-allergens, a
command which will initialize the allergens on the main interface.
Finish the command by typing end

5) To create mast-cells on the main interface, make a command called
to set-mast-cells. Under the command, define the shape of the
turtle (variable) by typing set-default-shape turtle “mast cell”.
6) Because mast cell is not already in the shape catalog for NetLogo,
you will need to draw your own. Under Tools click Turtles Shapes
Editor and press New. Name the shape mast cell and once you
finish drawing click Ok and exit the shapes editor. An example of a
shape that resembles a mast cell with IgE antibodies attached:
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7) Under set-default-shape turtled “mast cell” type create-mast-cells
initial-number-mast-cells which will allow you to initialize the
number of mast cells manually on the main interface
8) To define the position, size, and color of the mast cells in the
simulation, under
create-mast-cells initial-number-mast-cells type [ followed by (1)
setxy random-xcor random-ycor which will randomize the
distribution of mast cells across the screen. (2) set size 5 which
will make the mast cells larger than the other variables. If you
would like to try different sizes, try choosing other numbers
besides 5. (3) set color green which will make the mast cells green,
like with the size you can customize to any color of your choosing.
Finish the command by typing ] and end

9) To create allergens on the main interface, make a command called
to set-allergens. Under the command define the shape of the turtle
(variable) by typing set-default-shape turtle “circle”.
10) Under set-default-shape turtled “circle” type create-allergens
initial-number-allergens which will allow you to initialize the
number of allergens manually on the main interface
11) To define the position, size, and color of the allergens in the
simulation, under
create-allergens initial-number-allergens type [ followed by (1)
setxy random-xcor random-ycor which will randomize the
distribution of allergens across the screen. (2) set size .5 which will
make the allergens smaller than the mast cells (3) set color one-ofbase-colors which will make each of the allergens a random color.
Finish the command by typing ] and end
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12) Navigate back to the main interface by clicking Interface. You
might receive an error message saying certain variables have not
been defined but that is what we will do in the next few steps
13) Under Button click Button, place it near the top of the white part of
the main interface, name it setup, and click Ok. This will call back
to the to setup command you made earlier
14) Under Button click Slider, place it the white area of the main
interface and name it initial-number-mast-cells, and click Ok. This
will allow you to define the initial number of mast cells in the
simulation
15) Repeat step 14, but name this slider initial-number-allergens
which will allow you to define the initial number of allergens in the
simulation
16) You should no longer have any error messages. Click the setup
button which should populate the black screen with number of
mast cells and allergens indicated on the sliders in the colors,
sizes, and shapes you defined in the code
17) As it is now, the simulation is stagnant and you will need to code
in movement and interactions. Navigate back to the code by
clicking Code
18) Make a command called to go. Under to go type ask turtles
[move], followed by tick and end. You will need to also define move
(step 19) and tick indicates a passage of time in the simulation
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19) Make a command called to move. Under the command type (1) rt
random 100 which will have the turtles turn right at a random
angle, (2) lt random 100 which will have the turtles turn left at a
random angle, and (3) fd 1 which will move the turtle forward 1
patch. Finish the command by typing end

20) Navigate back to the main interface by clicking Interface. Under
Button choose Button and add it near the top of the white part of
the main screen, name it go, check the box that says Forever, and
click Ok. This will call back to you to go command in the code and
will allow the simulation to run continuously until go is clicked
again. You should now see the turtles moving around the black
screen. They are likely moving very fast, to slow the speed move
the speed slider near the top of the screen towards the left
21) As it is now the turtles do not interact in the simulation. In part 3
you will code in an interaction between the mast cells and
allergens which will model an allergic reaction
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Part Three: Model Testing and Advancement:

1) To define rules for the agents in the simulation you will need to
determine what you want the rules to be. Consider what happens
during an allergic reaction to an allergen and a mast cell.
Specifically, think about:

a.

How a reaction is initiated (e.g., is direct contact between a
mast cell and allergen necessary?).

b.

Are allergens used up during a reaction or can they renter
the blood steam?

c.

Are mast cells used up during a reaction?

d.

Can mast cells recognize multiple different types of
allergens?

e.

What products are formed due to an allergen and mast cell
interaction? [Hint: keep it simple, remember you already
defined a third breed of turtle that should suffice as your
products]

2) Using your considerations above determine at least 3 rules that
you will code into the model. For example:
a. A reaction will be initiated if a mast cell comes into contact with
an allergen for which it has a specific IgE antibody
b.

c.
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3) Identify any assumptions you may want to make in order to
decrease the complexity of your model. For example, in the tutorial
the assumption was made that IgE was already present on the
mast cells and therefore was not included in the simulation. An
additional assumption based on the rule defined above could be
that a mast cell will only need to come in contact with one allergen
to elicit a response.
a. Explain any additional assumptions:

4) Using these rules, determine the code that will need to be added to
the model to carry out the rules. Use NetLogo Dictionary
(http://ccl.northwestern.edu/netlogo/docs/index2.html) for help on
syntax and codes that are available. [Hint: the codes hatch, ask,
and die might be helpful]. An example of a code for the first rule
would be:

This code essentially asks if any mast cells come into contact with
a certain colored allergen. If true additional commands (what you
will write) should follow to simulate the response. It will likely take
several tries to get a code that works and is in the correct syntax.
To aid in troubleshooting, click Check at the top of the screen
which will indicate any errors. Also important, I introduced a new
variable allergy so if you used my code, you will need to define
what allergy is or simply change it to a color in the code [Hint: try
using the buttons in the main interface to allow manual input of a
color]. Finally, make sure to add have-reaction under the to go
command in order to initiate it when the simulation is started.
5) Once you have a working code, it is important to test that it works.
For example, to test the code provided, you could slow the
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simulation down and decrease the number of allergens and mast
cells in order to be able to watch carefully and ensure that a
reaction was only initiated when a mast cell came into direct
contact with an allergen of the color chosen. Come up with at least
two additional tests that you could perform to determine if your
code works. [Hint: this can include adding a plot button to measure
the amount of a certain variable, manipulating variables to see the
effect on the simulation, or visually watching for something to
happen].
a.

b.

6) Perform your tests. If your code is not performing how you
anticipated try troubleshooting or writing a new code and retry
your test.
a. Describe the outcome of your tests and troubleshooting
process.
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7) This model is extremely basic and has many limitations which do
not capture the full response of an allergic reaction.
a. In your opinion, what are the model’s three biggest
limitations? Especially consider any assumptions that were
made when answering this question.

b. Choose one of these limitations and describe what you think
should be added to the model to address this limitation.
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Module 4: Gene Regulation and Stability Using Boolean
Logic

Platform: NetLogo
Following this lesson students should be able to:
1) Describe the components that make up a lac operon and how it
functions
2) Apply Boolean logic to biological phenomena
3) Identify stability in a biological process and computational system
4) Evaluate model outputs to determine emergent phenomena
Purpose: This module will guide students through a tutorial to code a
NetLogo model from scratch that uses Boolean Logic to create a
simulation of the lac operon. Biologically, students will be exposed to a
common model of gene regulation. Computationally, students will define
rules using Boolean logic and analyze model outputs to identify a
system’s emergent phenomena.
Biological Terms:
1) Lac operon: the set of genes that regulate the creation of enzymes
to break down lactose
2) Promotor: the binding site of RNA polymerase
3) Repressor: a protein that inhibits the transcription of the lac
operon when lactose is not present
4) Operator: the binding site of the repressor protein
5) Lactose: the backup energy source
6) Glucose: the preferred energy source
7) Catabolite Activator Protein (CAP): a protein that becomes inactive
with high levels of glucose
8) RNA polymerase: the protein that transcribes the lac operon
9) CAP Site: the binding site of CAP which speeds up the
transcription of the lac operon when CAP is inactive
10) Transcription: the first step of expressing new proteins from
genetic material
Computational Terms:
1) Boolean Logic: a problem which reports only a True or False value
2) If: used to carry out a function only when a Boolean problem is
True
3) If Else: used to carry out two functions, one when a Boolean
problem is True and one when it is False
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4) Emergent phenomena: property that arises from the collective
behavior of a dynamic system
5) Stability: the ability to converge to an equilibrium across a range of
inputs or perturbations (unstable systems do not move toward an
equilibrium)
6) Bistability: two states of equilibrium in a dynamic system
Time Estimation:
1) In-Class Activity: 30 minutes
2) Model Tutorial: 1 hour
3) Model Testing and Advancement: 2 hours 30 minutes
Total: 4 hours
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Part One: In Class Activity

Materials: none
Rules:
1) Assign each student (or group of students) a role of the lac operon
(promotor, repressor, lactose, glucose, CAP, RNA polymerase,
enzymes)
2) Have students stand to represent an active state and sit to
represent an inactive state
3) Have students decide what must happen for them to reach an
active state (i.e. if they are the promotor, the repressor will need to
be sitting) and what will need to happen to reach an inactive state
(i.e. if they are lactose, enzymes will need to be standing)
4) Start with an inactive lac operon [Standing CAP and repressor]
[Sitting: lactose, glucose, RNA polymerase, enzymes]
5) The lactose and glucose students are the inputs. Play a game of
Simon Says If and If Else to determine their activation (i.e. If you
are wearing a red shirt stand, if else remain seated)
6) After each If/If Else command allow the students to reach stability
(i.e. no more changing of sitting vs. standing) before introducing
another command
7) Keep introducing commands to the lactose and glucose inputs for
multiple rounds. Make sure to give commands that reach all input
possibilities at least once [(1) just glucose standing, (2) just
lactose standing, and (3) both standing]
Suggested Discussion Questions:
1) How is sitting or standing a good representation of Boolean logic?
2) What were the different points of stability reached throughout the
activity?
3) Were there any components of the lac operon that Boolean logic
does not fully cover?
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Part Two: Model Tutorial

1) Open NetLogo
2) Instead of using one of the built-in codes, you will be making one
from scratch today. Click the Code tab to get started
3) Define the breeds of variables that will be part of the model using
breed [plural_form singular_form]. The components of this model
should include lactose, glucose, promotor, operator, repressor, lac
genes, RNA polymerase, enzymes, cap, and cap site

4) Define the global variable transcribe? with globals [transcribe?].
This variable will use Boolean logic to determine if the conditions
are met to turn on the lac operon
5) Define the turtle owned global variable age with turtles-own [age].
This variable will keep track of the age of the turtles

6) To set up the simulation, make a command called to setup. Under
the command, type 4 actions (1) clear-all, which will clear all
variables each time the code is run, (2) reset-ticks, which will
initialize the time to be 0, (3) make_operon, a command which will
create the lac operon, and (4) set transcribe? false, a command
that will set the Boolean logic gate as false at beginning of the
simulation. Finish the command by typing end
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7) To create the lac operon, make a command called to make_operon.
Under the command, create the 7 turtles that comprise the lac
operon: operator, promotor, repressor, cap site, cap, lac genes,
and RNA polymerase using the format create-breed 1 [ set color
____ set shape “____” setxy ____ ____ set size____]. You can
customize with your own preferences in the ____s and finish the
command with end
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8) Navigate to the main interface by clicking Interface and check to
see if your lac operon was built correctly. Under Button click
Button, place it near the top of the white part of the main interface,
name it setup, and click Ok. Click the setup button and your lac
operon should appear on the screen. If you used the above
commands, it will give you the lac operon pictured bellow. [Hint:
circle 3 for the RNA polymerase is not a default shape in the
NetLogo Turtle Shapes Library and will need to be created]

9) To add glucose to the model, make a command called to addglucose. Under the command type create-glucose 10 [set color
cyan set shape “circle” set size 1 setxy random-xcor random y-cor]
end.
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10) Navigate to the main interface by clicking Interface. Under Button
click Button, place it near the top of the white part of the main
interface, name it add-glucose, and click Ok. When this button is
clicked it will add 10 glucose molecules to the simulation
11) Repeat steps 9 & 10 to add lactose to the model in the code and
with the button. Instead of the color cyan, use magenta

12) While on the main interface, also add a plot to the screen. Under
Button click Plot and add it to the bottom of the white part of the
main screen. Right click on the plot and choose Edit. Name the plot
Gene Regulation, the x axis label Time, and the y axis label Amount
13) Under pen update commands change plot count turtles to plot
count glucose and change to default color from black to cyan by
clicking on the black box, choosing cyan, and clicking Ok.
14) Click add pen and repeat step 13 by naming the pen command,
plot count lactose and making the color magenta
15) Click add pen and repeat step 13 by naming the pen command,
plot count enzymes and making the color green. Click Ok to exit
the plot
16) Navigate back to Code. Make a command called to go under the
command type tick and end
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17) Navigate to the main interface by clicking Interface. Under Button
click Button, place it near the top of the white part of the main
interface, name it go, and click Ok. When this button is clicked it
will start the simulation. More commands will need to be added
under to go and the model to simulate the lac operon which you
will do in part three
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Module 4: Gene Regulation and Stability Using Boolean
Logic
1) To define rules for the agents in the simulation you will need to
determine what you want the rules to be. Consider how the lac
operon works (https://www.khanacademy.org/science/apbiology/gene-expression-and-regulation/regulation-of-geneexpression-and-cell-specialization/a/the-lac-operon). Specifically
think about:
a. When lactose is present what happens to the repressor?

b. How does the removal of the repressor effect transcription?

c. When glucose is present what happens to CAP?

d. How does the removal of CAP affect transcription?

e. What is produced as a result of transcription?

f. What parts of the lac operon including its inputs and
products move?

2) Using your considerations from above define the outcomes (rules)
for the Boolean Logic problems below. The first two have been
completed as examples
d. If lactose > 0

152

True: move repressor and start transcription
False: nothing
e. If else lactose >= (greater or equal to) glucose
True: fast transcription
False: slow transcription

f. If glucose > 0 [Hint: what happens to CAP?]
True:
False

g. If enzyme > lactose
True:
False:

h. If enzyme on lactose [Hint: what is the purpose of the enzymes
produced by the lac operon?]
True:
False:

3) Identify any assumptions you may want to make in order to
decrease the complexity of your model.

a.
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4) Using these rules and assumptions, determine the code that will
need to be added to the model to carry out the rules. Use NetLogo
Dictionary (http://ccl.northwestern.edu/netlogo/docs/index2.html)
for help on syntax and codes that are available. [Hint: the codes if
and ifelse should be very helpful and comprise most of the added
components. Also count, ask, die, any? and move should be
helpful]
5) Once you have a working code, it is important to test that it works.
Come up with at least 5 tests (one per rule) to determine if your
simulation is working properly.

a.

b.

c.

d.

e.
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6) Perform your tests. If your code is not performing how you
anticipated try troubleshooting or writing a new code and retry your
test.
b. Describe the outcome of your tests and the troubleshooting
process.

7) Analyzing how a simulation performs when varying input
parameters (i.e. changing the amount of lactose or glucose added
to the simulation) can uncover emergent phenomena of the model.
An emergence of the lac operon biologically and in this simulation
is it bistability. Using the Gene Regulation plot from the simulation
explain how we can make this conclusion.
a.

8) This model is extremely basic and has many limitations which do
not capture the full workings of a lac operon.
a. In your opinion, what are the model’s three biggest
limitations? Especially consider any assumptions that were
made when answering this question.
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b. Choose one of these limitations and describe what you think
should be added to the model to address this limitation.
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Module 5: The Menstrual Cycle Using Boolean Logic

Platform: NetLogo
Following this lesson students should be able to:
1) Describe the hormones that contribute to the menstrual cycle and
how they function
2) Apply Boolean logic to biological phenomena
3) Identify stability in a biological process and computational system
4) Evaluate model outputs to determine emergent phenomena
Purpose: This module will guide students through a tutorial to code a
NetLogo model from scratch that uses Boolean Logic to create a
simulation of the menstrual cycle. Biologically, students will be exposed
to the hormones involved in the menstrual cycle. Computationally,
students will define rules using Boolean logic and analyze model outputs
to identify a system’s emergent phenomena.
Biological Terms:
1) Follicular Phase: the period of the menstrual cycle from the first
day of the period until ovulation. Starts with the release of FSH and
continues as estrogen slowly builds up
2) Luteal Phase: the period of the menstrual cycle from the start of
ovulation until the period starts. Progesterone peaks and then
drops
3) Follicle Stimulating Hormone (FSH): released from the pituitary
gland and stimulates the maturation of an egg in the ovaries
4) Progesterone: released by the corpus luteum after ovulation. If
fertilization of an egg does not occur, the corpus luteum dies and
levels drop
5) Estrogen: released by the ovaries. Levels rise and fall twice within
the menstrual cycle
6) Luteinizing Hormone (LH): released from the pituitary gland due to
high estrogen levels
7) Ovulation: the release of an egg. Triggered by a spike in LH
Computational Terms:
1) Boolean Logic: a problem which reports only a True or False value
2) If: used to carry out a function only when a Boolean problem is
True
3) If Else: used to carry out two functions, one when a Boolean
problem is True and one when it is False
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4) Emergent phenomena: property that arises from the collective
behavior of a dynamic system
5) Stability: the ability to converge to an equilibrium across a range of
inputs or perturbations (unstable systems do not move toward an
equilibrium)
Time Estimation:
1) In-Class Activity: 30 minutes
2) Model Tutorial: 1 hour
3) Model Testing and Advancement: 2 hours 30 minutes
Total: 4 hours
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Part One: In Class Activity

Materials: none
Rules:
1) Assign each student a component/hormone in the menstrual cycle
(5 FSH, 5 LH, 5 progesterone, 5 estrogens, 1 egg (ovulation))
2) Have students stand to represent an active state and sit to
represent an inactive state
3) Have students decide what must happen for each component to
reach an active state (i.e. all LH stand up if 5 estrogen and 3 FSH
are standing) and what will need to happen to reach an inactive
state (i.e. all LH sit if egg is standing)
4) Start with everyone sitting
5) Play a game of Simon Says If and If Else to determine their
activation (i.e. If you are wearing a red shirt stand, if else remain
seated)
6) After each If/If Else command allow the students to determine if
who is standing would be part of the menstrual cycle (i.e. if it
follows one of the rules outlined in step 3). If so have them cycle
7) Keep introducing commands until they have cycled at least three
times
Suggested Discussion Questions:
1) How is sitting or standing a good representation of Boolean logic?
2) What components of the menstrual cycle does Boolean logic does
not fully cover?
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Part Two: Model Tutorial

1) Open NetLogo
2) Instead of using one of the built-in codes, you will be making one
from scratch today. Click the Code tab to get started
3) Define the breeds of variables that will be part of the model using
breed [plural_form singular_form]. The components of this model
should include estrogen, progesterone, LH, FSH, ovaries, fallopian
tubes, uterus, and eggs

4) Define the global variable ovulate? with globals [transcribe?]. This
variable will use Boolean logic to determine if the conditions are
met to turn on the lac operon
5) Define the turtle owned global variable age with turtles-own [age].
This variable will keep track of the age of the turtles
6) To set up the simulation, make a command called to setup. Under
the command, type 4 actions (1) clear-all, which will clear all
variables each time the code is run, (2) reset-ticks, which will
initialize the time to be 0, (3) make_reproductive-system, a
command which will create the lac operon, and (4) set ovulate?
false, a command that will set the Boolean logic gate as false at
beginning of the simulation. Finish the command by typing end

7) To create the lac operon, make a command called to
make_reproductive-system. Under the command, create the 7
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turtles that comprise the beginning of the model: uterus 1, uterus
2, fallopian tube 1, fallopian tube 2, ovaries x2, and FSH using the
format create-breed 1 [ set color ____ set shape “____” setxy ____
____ set size____]. You can customize with your own preferences
in the ____s and finish the command with end

8) Navigate to the main interface by clicking Interface and check to
see if your reproductive system was built correctly. Under Button
click Button, place it near the top of the white part of the main
interface, name it setup, and click Ok. Click the setup button and
your lac operon should appear on the screen. If you used the
above commands, it will give you the reproductive system and FSH
pictured below. [Hint: uterus, fallopian tube 1 and 2, and ovaries
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are not a default shape in the NetLogo Turtle Shapes Library and
will need to be created]

9) Navigate back to the Code and create a command called to
follicular-phase. Initiate Boolean logic with if not ovulate? This will
run only if ovulate? is set to FALSE. Create command if count LH=
0 and if any? FSH on ovaries ask n-of 1 FSH on ovaries to hatcheggs and hatch-estrogen and ask n-of 3 FSH [die]. When LH=0
while ovulate? is FALSE, when FSH is on ovaries, eggs will
develop and estrogen will be created. Create command ask eggs
and if age= 100 [set size .5] and if age=500 [set size .75]. This will
have eggs get larger as they mature

10) Within to follicular-phase if not ovulate?, create code if count
estrogen = 20 and hatch-LH 100, hatch-FSH 30, and hatch-
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estrogen 40. This will have LH, FSH, and estrogen spike when
ovulate? is FALSE and estrogen = 20

11) Within to follicular-phase if not ovulate?, create code if count
estrogen = 60 and ask up-to-n-of 9 eggs [die] and set ovulate?
TRUE. This will have all but 1 egg die and set ovulate? TRUE when
estrogen= 60

12) Create command to go and tick, ask turtles [ follicular-phase,
move, age-up, if ovulate? [luteal-phase]]

13) Create command to age-up [ask eggs [set age age + 1]. This will
have eggs age up

14) Create command to move ask FSH, estrogen, LH, and
progesterone to randomly move
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15) Navigate to the main interface by clicking Interface. Under Button
click Button, place it near the top of the white part of the main
interface, name it go, and click Ok. When this button is clicked it
will start the simulation
16) While on the main interface, also add a plot to the screen. Under
Button click Plot and add it to the bottom of the white part of the
main screen. Right click on the plot and choose Edit. Name the plot
Hormone Levels, the x axis label Time, and the y axis label Amount
17) Under pen update commands change plot count turtles to plot
count FSH and change to default color from black to cyan by
clicking on the black box, choosing cyan, and clicking Ok.
18) Click add pen and repeat step 17 by naming the pen command,
plot count estrogen and making the color yellow
19) Click add pen and repeat step 17 by naming the pen command,
plot count LH and making the color orange. Click Ok to exit the plot
20) Click add pen and repeat step 17 by naming the pen command,
plot count progesterone and making the color red. Click Ok to exit
the plot
21) This tutorial has helped create half the menstrual cycle, you will
need to create the luteal phase and a way for the model to continue
cycling. [Hint: setting the time step slower will help]
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Part Three: Model Advancement and Testing

1) To define rules for the luteal phase the simulation you will need to
determine what you want the rules to be. Consider this graph of
the hormone levels in the menstrual cycle:

a. When does progesterone start to rise?

b. What happens to LH and FSH during the luteal phase?

c. What happens to estrogen during the luteal phase?

d. What happens to the egg during the luteal phase, how does
it move?

e. What must occur for the simulation to cycle?
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2) Using your considerations from above define at least five
outcomes (rules) using Boolean Logic. The end goal should be to
have your graph look very similar to the one provided and for the
egg to ovulate. Anything else you do to make the model more
accurate is up to you! [Hint: look through provided code of follicular
phase for assistance]

a.

b.

c.

d.

e.

3) Identify any assumptions you may want to make in order to
decrease the complexity of your model.

a.
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4) Using these rules and assumptions, determine the code that will
need to be added to the model to carry out the rules. Use NetLogo
Dictionary (http://ccl.northwestern.edu/netlogo/docs/index2.html)
for help on syntax and codes that are available. [Hint: the codes if
and ifelse should be very helpful and comprise most of the added
components. Also count, ask, die, any? and move should be
helpful. Look at the provided code for the follicular phase for
assistance]
5) Once you have a working code, it is important to test that it is
accurate. Come up with at least 5 tests (one per rule) to determine if
your simulation is working properly.

a.

b.

c.

d.

e.

6) Perform your tests. If your code is not performing how you
anticipated try troubleshooting or writing a new code and retry your
test.
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c. Describe the outcome of your tests and the troubleshooting
process.

7) This model is extremely basic and has many limitations which do
not capture the full workings of a lac operon.
a. In your opinion, what are the model’s three biggest
limitations? Especially consider any assumptions that were
made when answering this question.

b. Choose one of these limitations and describe what you think
should be added to the model to address this limitation.
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